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ENGLISH	SUMMARY	
Quality improvement is increasingly used in the healthcare sector in an attempt to, 
amongst other things, contain the increasing resource use. Health economic evaluation 
informs on the efficient use of resources and hence could provide valuable 
information on the value for money of quality improvements. However, in quality 
improvement, quality indicators are often favored for assessment of the impact of 
interventions. As quality indicators do not necessarily represent an impact on health, 
per se, this constitutes an obstacle for the economic evaluation of quality 
improvements. In addition, there are appreciable differences in the aims and 
epistemologies of economic evaluation and quality improvement. Economic 
evaluation is intended to inform on the value for money of interventions and evidence 
on the value of interventions is often derived from evidence-based medicine. In 
contrast, quality improvements may target other aspects of healthcare than the 
efficient allocation of resources and evidence is acquired through a multiplicity of 
methods from different scientific disciplines. These discrepancies constitute 
substantial barriers to the application of economic evaluation of quality 
improvements. In consequence, establishment of their value for money may be 
hampered. The lack of knowledge on the cost-effectiveness of quality improvements 
may indirectly harm patients by causing opportunity costs – either because cost-
effective quality improvements are not implemented or because cost-ineffective 
interventions are employed.  
The present dissertation presents a contribution as to how quality indicators may be 
employed to estimate the value for money of quality improvements, when evidence 
on their impact on patient-relevant outcomes is not available. In a framework founded 
in Bayesian decision theory and value-of-information analysis, quality indicators may 
be introduced as intermediate links between interventions and patient-relevant 
outcomes, thereby enabling estimation of the cost-effectiveness of quality 
improvements. A set of requirements for quality indicators to be applicable in the 
context of economic evaluation is propounded. These lead to the presentation of a set 
of methodological considerations, which should be made when studies in quality 
improvement are designed and economic evaluation is projected. 
The empirical case for the present dissertation and the appended papers is within the 
clinical field of cardiology, specifically on stroke prophylaxis in nonvalvular atrial 
fibrillation through the use of oral anticoagulant therapy. The focal point of the papers 
is to evaluate the health economic potential of alternative approaches to improving 
stroke prophylaxis for this patient population, not focusing on evaluation of one 
pharmacological treatment versus another.   

IX 
DANSK	RESUME	
Kvalitetsudvikling bliver i stigende grad brugt indenfor sundhedssektoren, blandt 
andet i et forsøg på at dæmme op for det stigende forbrug af ressourcer. Sundheds-
økonomiske evalueringer bruges til at belyse, hvorledes ressourcerne kan anvendes 
mest efficient, så der opnås mest sundhed for pengene. De kunne derfor være en vigtig 
kilde til viden om den værdi for pengene, der kan opnås via kvalitetsudviklende tiltag. 
Kvalitetsindikatorer bruges ofte indenfor kvalitetsudvikling til at påvise effekten af 
interventioner, men da kvalitetsindikatorer i sig selv dog ikke nødvendigvis afspejler 
effekt på sundhed, udgør brugen af dem en hindring, når man ønsker at lave 
informative sundhedsøkonomiske analyser.  
Ydermere er der betydelige, grundlæggende forskelle mellem sundhedsøkonomisk 
evaluering og kvalitetsudvikling; både hvad angår deres formål og epistemologiske 
baggrund. Formålet med sundhedsøkonomisk evaluering er som sagt at belyse den 
værdi for pengene, som interventioner leverer, og evidensen, der anvendes, stammer 
som oftest fra evidensbaseret medicin. I modsætning kan kvalitetsudvikling være 
rettet mod andre aspekter af sundhedspleje end den efficiente fordeling af ressourcer, 
og evidens for effekten af kvalitetsudviklende tiltag kan indhentes ved hjælp en 
mangfoldighed af metoder, der udspringer af flere forskellige videnskabelige 
discipliner. Disse uoverensstemmelser udgør en betydelig udfordring for 
sundhedsøkonomisk evaluering af kvalitetsudviklende tiltag og som konsekvens 
heraf, kan det være svært at vurdere deres værdi for pengene. Manglende viden 
omkring omkostningseffektiviteten af kvalitetsudviklende tiltag kan være til indirekte 
skade for patienter, idet det kan påføre alternativomkostninger – enten som følge af at 
omkostningseffektive interventioner ikke bliver implementeret, eller fordi 
omkostningsineffektive interventioner bliver anvendt.  
Denne afhandling præsenterer et bidrag til, hvordan kvalitetsindikatorer kan anvendes 
til at estimere omkostningseffektiviteten af kvalitetsudviklende tiltag, når der ikke 
findes evidens for disses effekt som målt via patient-relevante udfald. Med 
udgangspunkt i en Bayesiansk beslutningsteoretisk og value-of-information analytisk 
tilgang, vil kvalitetsindikatorer kunne introduceres som intermediære led i 
sammenhængen mellem interventioner of patient-relevante udfald. Dette vil 
efterfølgende kunne gøre det muligt at estimere omkostningseffektiviteten af 
kvalitetsudviklende interventioner. I afhandlingen opstilles en række betingelser til 
kvalitetsindikatorer, som skal opfyldes, for at disse vil være anvendelige som inputs i 
sundhedsøkonomiske evalueringer. Opstillingen af disse betingelser leder ydermere 
til en række metodologiske overvejelser, som bør tage i betragtning i forbindelse med 
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designet af studier af kvalitetsudvikling, såfremt det påtænkes at lave efterfølgende 
sundhedsøkonomiske evalueringer.  
Afhandlingen og de tilhørende studier tager empirisk udgangspunkt indenfor det 
kliniske område kardiologi, nærmere bestemt i den forebyggende behandling af 
slagtilfælde hos patienter med nonvalvulær atrieflimren ved hjælp af orale 
antikoagulantia. Omdrejningspunktet for studierne er at evaluere det 
sundhedsøkonomiske potentiale ved alternative tilgange til forbedring af den 
forebyggende behandling af slagtilfælde for denne patientgruppe, hvor der ikke 
fokuseres på sammenligningen af et medikament overfor et andet.   
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CHAPTER	1. 	
INTRODUCTION		
1.1. THE	INSATIABLE	HEALTHCARE	MONSTER	
In the continuous pursuit of improving the health of patients, innovative healthcare 
solutions are essential. Innovation in healthcare and healthcare technology incessantly 
increases the range of effective treatment options available for alleviation of the 
ailments of patients. Amongst other due to the progress in medical technology, 
massive changes and advancements have occurred with respect to health and 
healthcare within the last 150 years. Since the 1900s, infectious and parasitic diseases 
have no longer been the leading causes of morbidity and mortality worldwide and, 
particularly since the 1950s, longevity has increased in developed and developing 
countries alike. Instead, the prevalence and incidence of chronic diseases, such as 
coronary heart disease, type 2 diabetes, cancer, and stroke, have increased and now 
constitute the leading causes of morbidity and mortality. The increase in chronic 
diseases has occurred in concert with a change in the world demography, as the 
population ages.[5] Though enhanced longevity is inherently desirable, the 
concomitant epidemiological transition places healthcare systems and economies 
under substantial pressure. In Denmark, it has been estimated that approximately two 
thirds of the population suffer from one or more chronic diseases[6], thereby 
emphasizing the great public health challenge chronic conditions pose today. 
Improved knowledge on disease progression and how it may be abated has increased 
the call for, and availability of, treatments for chronic conditions, both 
prophylactically and to diminish the risk of late complications of diseases[5].  
Within the last decade, healthcare costs have increased globally as well as 
nationally[7]. In 2014, the total expenditure on health in Denmark accounted for 10.6 
percent of the gross domestic product. The 2014 expenditure of publicly funded 
healthcare alone added up to more than 170 billion Danish kroner (DKK) (2017 value) 
in Denmark, accounting for approximately 30 percent of the total public 
expenditure.[7,8] If the current developments continue, projections suggest that the 
healthcare expenditures will have increased by 47 percent by 2060[9]. As with other 
costs in the healthcare system, the costs of medications inside and outside hospitals 
have increased over time; in 2014, the cost of all medications amounted to more than 
13 billion DKK[10]. In Denmark, a Beveridge model for organization of the 
healthcare system has been adopted, in which the majority of the integrated healthcare 
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is completely financed by taxes, with the exception of some costs related to dental 
treatment and medications. Thus, the healthcare authorities are the single payer and 
are responsible for the supply of healthcare and the containment of the costs related 
to it.[11]  
The progress in new medical technology permits delivery of improved healthcare of 
both acute and chronic conditions, but usually it comes at an additional cost. The 
increased longevity of population puts healthcare systems and economies under 
pressure and the use of relatively costly new treatment for chronic conditions only 
exacerbates the scarcity of resources.[9,12–14] The availability of an arsenal of 
effective though costly treatments makes demands on decision-makers when 
budgetary constraints preclude the utilization of all potential treatments. The need for 
healthcare never ceases. Unless further resources are added, which would only 
transfer the pressure to other public sectors, the scarcity of resources within the 
healthcare system represents an impediment for the sustained utilization of clinically 
optimal therapies, if they come at too high a cost. For this reason, prioritization is 
expedient[11,13]. Prior to policy decisions on which interventions should be approved 
for utilization in a publicly funded healthcare system, such as the Danish one, it is 
highly relevant to acknowledge and evaluate the expected value for money of 
interventions to enable informed decision-making on the consequences of  the 
allocation of the scarce resources. Economic evaluation, identifying the value for 
money of medical technology, is a requirement for reimbursement decisions to be 
made in many countries with publicly funded healthcare systems[13,14]. In Denmark, 
attention to the cost-effectiveness of interventions has increased of late and different 
steps are taken to contain the costs and reduce the escalation of the expenditure[9,15].  
The pursuit of constraining healthcare costs, while still providing high-quality 
healthcare, has stimulated alternative approaches to healthcare optimization, aside 
from the utilization of more effective and safe medical technology. These approaches 
include quality improvement within existing healthcare[16–18].  
 
1.2. QUALITY	IMPROVEMENT	–	A	KEY	TO	COST	CONTAINMENT?	
Since the turn of the millennium, the focus in healthcare research has increasingly 
been turned towards the possibility of achieving increased patient safety, improved 
therapy, and cost savings through quality improvements within existing healthcare. 
The increased interest in quality of care has been spurred by changes in public 
healthcare systems and their reimbursement systems that might affect the quality of 
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care.[18–20] Consequently, quality in healthcare and quality improvement have been 
a part of the official, political agenda both nationally and internationally since 
approximately 2000. In Denmark, national strategies for quality improvement in the 
healthcare system are therefore continuously presented that include explicit quality 
aims dictating the trends in quality improvement work and research. Prior to the 
introduction of centralized management of quality improvement in Denmark, quality 
improvement was managed in a decentralized way by dedicated healthcare 
personnel.[19,21,22]  
One of the main purposes of assessing quality and quality improvement has been to 
support administrative and social policy decisions, by indicating which initiatives 
might produce beneficial results[23,24], and the methods for evaluating quality 
improvements have been developed and utilized with this in mind. Assessment of the 
quality of healthcare is increasingly important to providers, purchasers, and regulators 
of healthcare, as budgetary constraints enforce considerations of the expected benefit 
of interventions and their subsequent value for money[20]. Consequently, quality 
improvement may in the future be subjected to the same requirements for evidence of 
cost-effectiveness as those for medical technology. Explicit evaluation of the cost-
effectiveness of interventions has, however, not traditionally been a part of the 
evaluation of quality improvements and the methods for economic evaluation of 
quality improvement remain mostly unexplored[16,18,25]. Discrepancies in the 
currently used methods for economic evaluation and the very methodology of quality 
improvement in healthcare challenges the design of economic evaluation within this 
field of research. Incongruence in the scientific foundation may cause problems as 
health economic methods have been developed to address other challenges than those 
that present themselves in research on quality improvement[24,26]. For instance, a 
prevalent and increasing challenge is the use of quality indicators (QIs) for assessment 
of effect of quality improvements[20,27]. These effect measures often do not reflect 
impact on health, per se, which represents an obstacle to economic evaluation of the 
value for money of quality improvements. This may complicate informed decision-
making within healthcare if the expected value for money of quality improvements 
cannot be established. It may ultimately cause suboptimal policy decisions leading to 
opportunity costs if inferior interventions are opted for due to a lack of knowledge of 
their comparative cost-effectiveness.  
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1.3. OPTIMIZING	ORAL	ANTICOAGULANT	THERAPY		
IN	ATRIAL	FIBRILLATION	
Within the last decade, several advancements have occurred with respect to the 
treatment of patients with the chronic, cardiac arrhythmia, nonvalvular atrial 
fibrillation (i.e. excluding valvular atrial fibrillation, hereafter only referred to as AF). 
Greater understanding of the disease itself and the availability of new therapies have 
led to the rapid development of clinical practice guidelines on clinically appropriate 
treatment of this condition. The guidelines recommend that the majority of patients 
with AF should be treated prophylactically with continuous oral anticoagulant therapy 
(OAC) to avoid stroke and other thromboembolic complications, which the condition 
predisposes to.[28,29] Sustained thromboprophylaxis through the use of OAC for 
eligible patients with AF constitutes the clinical focus for the present dissertation. 
In Denmark, thromboprophylaxis through the use of OAC is mainly achieved by the 
use of the vitamin K antagonist warfarin and the newer OAC agents, non-vitamin K 
oral anticoagulants (NOACs)[29–31]. The emergence of the NOACs for stroke 
prophylaxis in AF is assumed to be the triggering factor for a raised awareness of the 
clinically appropriate treatment of this patient population and for an increased spread 
of appropriate treatment. Both in Denmark and internationally, more patients with AF 
are now treated in accordance with clinical practice guidelines on stroke prophylaxis 
in AF than was observed just four years ago. This has also entailed an increased use 
of NOACs for stroke prophylaxis in AF and a stagnation in the utilization of warfarin 
therapy, which has otherwise been used for stroke prophylaxis for decades.[29,32,33]  
A main difference between the agents is the level of monitoring that is necessary to 
ensure that the effectiveness and safety of the therapies are maintained. Whereas 
warfarin therapy necessitates relatively frequent monitoring, which may be a nuisance 
to patients and represent an additional cost of therapy delivery, this is not necessary 
for the NOACs[34]. Though increased use of OAC, and especially the NOACs, for 
stroke prophylaxis in AF represents a clinical improvement of the therapy of patients 
with AF, it also increases the current pressure on healthcare budgets, as the purchase 
cost of NOACs is substantially higher than that of warfarin[35].  
Within the last decade, the comparative cost-effectiveness of the NOACs versus 
conventionally managed warfarin therapy has been investigated thoroughly[36–38]. 
These analyses have typically investigated the cost-effectiveness of substituting one 
therapy with another, based on evidence from large randomized controlled trials 
(RCTs)[39–42]. However, other initiatives in OAC exist that likewise may improve 
the health of the AF patient population as a whole. For instance, adherence to current 
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clinical practice guidelines may be improved, ensuring a larger proportion of patients 
receive clinically appropriate therapy. Quality improvements, such as improving 
guideline adherence, may represent important approaches when the aim is to improve 
the health of patients. 

7 
CHAPTER	2. 	
HYPOTHESIS	AND	THESIS	AIMS	
The basic hypothesis in the present dissertation is that economic evaluation may 
represent a useful tool for establishing the value for money of quality improvements 
in healthcare and that, though economic evaluation cannot encompass all aspects 
relevant to informed policymaking, it constitutes a rational premise for the decision-
making to be sound. This dissertation presents a contribution to exploring that 
hypothesis within the empirical field of research on OAC stroke prophylaxis in AF. 
The present thesis thus intends to: 
1) INVESTIGATE OPPORTUNITIES FOR IMPROVING ORAL ANTICOAGULANT 
THERAPY OF PATIENTS WITH ATRIAL FIBRILLATION 
and 
2) INVESTIGATE THE OPPORTUNITIES AND OBSTACLES ASSOCIATED WITH 
ECONOMIC EVALUATION OF QUALITY IMPROVEMENTS WHEN PATIENT-
RELEVANT OUTCOMES ARE NOT AVAILABLE AND PRESENT A CONTRIBUTION 
AS TO HOW THE OBSTACLES MAY BE OVERCOME 
Quality in healthcare may be increased by a vast number of methods and knowledge 
of how their health economic impact should be estimated is currently incomplete. The 
clinical aim of the present dissemination is to seek cost-effective approaches to 
optimize therapy for this patient population, not necessarily focusing the use of new 
medical technology.  
In the present dissertation, the focus is on static, comparative evaluation of quality 
improvements. As such, the approach to economic evaluation is based on the available 
evidence on the impact of quality improvements without projections of potential 
changes in the impact over time. The impact of quality improvements is expected to 
be constant over time. Unsubstantiated assumptions on potential increase or decrease, 
as would likely be observed in real life, are not included. This is consistent with the 
methods for economic evaluation of medical technology, ensuring comparability of 
the expected cost-effectiveness of interventions irrespective of the type of intervention 
under investigation. Increasing knowledge in this area may have social and scientific 
bearing as it may aid informed policymaking in healthcare. The appended papers 
(Appendix A–D) are intended to support the exploration of the hypothesis and aims 
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of the present dissertation. They are presented as illustrative examples of how 
evaluation of potential quality improvements may be enabled and should not be 
considered exhaustive. 
Chapter 3 of this dissertation presents an account of the purpose of the healthcare 
system, which both the methods of health economics and quality improvement in 
healthcare are intended to support. The chapter therefore includes a brief introduction 
to the foundations and epistemological background of the two scientific fields of 
quality improvement and health economics, with a specific focus on the methods for 
economic evaluation, to illustrate the discrepancies and similarities between them. 
Acknowledgement of these is pivotal to the understanding of the opportunities and 
obstacles that exist for the application of economic evaluation to quality 
improvements. The chapter aims to provide an overview of the dominant theories and 
premises that form the foundation for the methods for economic evaluation and 
modern quality improvement. It is not intended to cover all aspects and methodologies 
of either health economics or quality evaluation and improvement. 
Chapter 4 includes an introduction to the clinical field of AF and research on stroke 
prophylaxis in AF through the use of OAC. The chapter aims to highlight the necessity 
and challenges of OAC in AF, the current developments in OAC stroke prophylaxis, 
the challenges in procuring sufficient evidence on the effectiveness and safety of 
agents, and potential focus areas for quality improvement. The prevalence of AF is 
relatively low and, luckily, complications occur only relatively infrequently. 
Consequently, the effectiveness and safety of interventions to stroke prophylaxis is 
sometimes evaluated through the use of QIs. OAC in AF thus represents a relevant 
empirical case for the present thesis. 
Chapter 5 includes summaries and discussions of the individual papers included in the 
thesis. It also includes a contextualization of them within the frame story of the 
dissertation.  
Lastly, Chapter 6 discusses the potentials of applying economic evaluation to the area 
of quality improvement in healthcare, as supported by the papers and the dissertation 
itself. It includes suggestions of a set of considerations that should be included in 
future work to potentially enable the application of economic evaluation to quality 
improvement, when patient-relevant outcomes are not available. 
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CHAPTER	3. 	
METHODOLOGY	
3.1. PURPOSE	OF	THE	HEALTHCARE	SYSTEM	
The main objective of the Danish healthcare system is explicated in the first section 
of the Danish Health Care Act, which states that “The healthcare system aims to 
increase the health of the population and to prevent and treat illness, suffering, and 
infirmity for the individual” [author’s translation][43]. Thus, the main purpose of the 
healthcare system and therefore implicitly also interventions provided by the 
healthcare system, is to bring relief of pain and illness in order to improve health to 
the benefit of individuals and the society as a whole[26,43]. As such, the aim of 
healthcare is not to increase the products of the healthcare system, such as surgery, 
bed days, or medication, etc. These entities do not bring patients utility, per se, but 
constitute the means to an end, i.e. the obtainment of health. [11] The World Health 
Organization (WHO) has defined health as “a state of complete physical, mental and 
social well-being and not merely the absence of disease or infirmity”[44]. According 
to this definition, health comprises more aspects than just the physical health of 
individuals, interpreted as their bodily functioning. This interpretation of health is 
pivotal when evaluating the effectiveness of interventions that are aimed at 
maximizing the health of patients.  
Policymakers within the healthcare system direct the focus of healthcare and decide 
its purpose, as explicated in the Danish Health Care Act[43]. There is a widespread 
assumption that decision-makers intend to maximize the health of the population, but 
they must do so within existing budgetary constraints[11,14]. Accepting the premise 
that the purpose of the healthcare system is to maximize health outcomes and that this 
must be done with only a certain amount of available resources, the average expected 
health benefits and additional costs related to actions within the healthcare system 
should be decision-makers’ primary concern[13].   
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3.2. FOUNDATIONS	OF	HEALTH	ECONOMICS	
Health economics concerns the application of economic methods within the area of 
health and healthcare. As the field of the discipline, i.e. health and healthcare, is not 
embedded within the scientific field of normative economics, health economics 
comprises elements from various scientific disciplines, including social, health, and 
natural sciences. Consequently, application of health economic methods often 
requires a multidisciplinary approach that appreciates and incorporates the complexity 
of the functioning of the healthcare system to generate analyses that may substantiate 
sound policy decisions.[11] 
Identified as a subdiscipline within economics, specialized in health and healthcare 
delivery, health economics is founded in microeconomics and welfare economics. As 
such, the methods used in health economics adopt the expectation that resources, both 
monetary and nonmonetary, are scarce and must be allocated to competing purposes. 
This is on a par with the observed reality in healthcare. Furthermore, it is expected 
that all decision-making concerning health and healthcare is based on rationality and 
an inherent desire for maximization of ‘benefit’. This entails all players within the 
healthcare system, including patients, clinicians, and policymakers, choosing the 
courses of actions that provide them with the largest maximand and being able to rank, 
for instance, interventions based on their desirability under budgetary restrictions. It 
follows that policymakers who make decisions on the functioning of the healthcare 
system and utilization of its scarce resources are expected to be rational and have an 
inherent desire to maximize the ‘benefit’ for the society that they represent.[11,45] 
Welfare economics constitutes the normative basis for health economics and provides 
the value-based, theoretical framework in which economic evaluation is performed. 
Within normative health economics, the objective of actions, e.g. policy decisions, is 
predefined via the philosophical foundation of welfare economics. The actions are 
valuated against that objective. The philosophical foundation and ethical theory of 
welfare economics are often recognized to be, basically, utilitarianism. In 
utilitarianism, the ethical optimum is the situation that generates the total maximum 
amount of utility of all individuals in a society, i.e. the greatest social welfare[46]. 
Roughly described, “Utility is a measure of [the individual’s, ed. by author] level of 
satisfaction with various combinations of consumer goods. It includes a market basket 
filled with a combination of housing, food, transportation, and so on, with perhaps 
many types of each”[46]. Each individual has an index of preferences towards a 
multitude of ‘goods’ or states of the world, which may change depending on the 
conditions that he or she experiences. An individual’s preferences towards the goods 
or states of the world and ability to weigh their importance against each other generate 
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a utility function, where some elements are given a higher preference than others. 
When an individual is able to attain a state of the world that he/she has a higher 
preference for than his/her prior state, this indicates that the individual has achieved a 
higher level of utility. As preferences for states of the world are individually decided, 
the utility that may be expected from different states is not transferable between 
individuals. Accordingly, in the welfarist evaluation only individual utility can be 
used as an outcome for evaluation. The aggregate of all individuals’ experienced 
utility within a society constitutes the level of social welfare. Therefore, if an 
individual achieves a state of the world that he or she prefers compared to the prior 
state this will, consequently, also increase the total level of social welfare.[46,47]  
Adopting a utilitarian ethical foundation, the dominant framework in welfare 
economics for the assessment of, for example, interventions has adopted four explicit, 
normative key tenets presented in Box 1. These comprise the cornerstones of the 
framework for welfare economist evaluation.[11,46,47]  
 
Welfare economics is used in the pursuit of maximizing total social welfare. It then 
follows that the immediate purpose of welfare economics is to maximize benefit 
within budgetary constraints, i.e. to identify the optimal resource allocation that 
ensures the lowest cost per unit of the maximand. [11,47] The optimum, the Pareto-
efficient situation is achieved when the maximand is the highest possible and when 
no reallocation of resources can be made where the benefit of one individual is 
optimized without making that of another individual worse. Traditionally, it is 
assumed that Pareto efficiency, also known as optimality, may be achieved in a 
perfectly competitive market. The importance of this assumption in welfare 
I. The utility principle. The expectation that individuals are able to rationally 
order options based on their expected benefit and will maximize their own 
welfare accordingly by choosing the preferred option. Individuals’ utility 
is unaffected by what happens to other individuals. 
 
II. Individual sovereignty. Individuals are the best judges as to what brings 
them the greatest utility. Individuals’ preferences towards different ‘goods’ 
differ. Utility is contingent on the individuals’ preferences towards the 
‘goods’. Consequently, it is not possible to compare or aggregate utility 
across individuals. 
 
III. Consequentialism. Welfare is derived from the final result of actions and 
processes and not the processes themselves. 
 
IV. Welfarism. The benefit of a situation should be evaluated based on the level 
of social welfare it provides.  
Box 1. Normative key tenets for the welfare economist framework for evaluation[47]. 
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economics is emphasized by the reference to it as ‘the first fundamental theorem of 
welfare economics’[46]. However, the requirements that substantiate the competitive 
model, and to some degree the very tenets that substantiate the framework for welfare 
economic evaluation, are not observed in the healthcare system.[11,46] This has led 
to criticism of the welfare economist approach to the evaluation of healthcare.  
A particularly influential critique of the welfare economist approach to the evaluation 
of healthcare has been put forward by Sen, who criticized the very foundation of 
welfare economist evaluation by calling into question the use of individual utility as 
the sole outcome in the evaluation of healthcare. By definition, utility reflects an 
individual’s emotional reaction, e.g. satisfaction (Box 1), to the possession of goods 
and capabilities[46]. However Sen argues that the usefulness, i.e. the enablement and 
potential capabilities,  that ‘goods’ or states of the world would impart to individuals 
is of higher relevance as an outcome for measurement[47]. In traditional welfare 
economics, health is considered a commodity equal to any other goods that may be 
valuated, purchased, and consumed. It could, however, be argued that sound, or at 
least adequate, health is a prerequisite for the consumption of other goods. Thus, 
health holds an ‘extra’ value, which distinguishes it from other commodities. If 
individuals do not possess a certain level of health, they may not be able to value or 
utilize other goods, for which reason health and consequently healthcare provision as 
a means for obtaining health is a necessity rather than a normal good. Furthermore, 
the health of the population is also meritorious for the maintenance of a functioning 
workforce and the productivity in society. Therefore, health represents an entity of 
such high importance for the very functioning of society that it could be argued that 
health and other commodities should not be given the same weight.[46,47] This is 
also used as argument for the view that the maintenance of the health of the population 
should be subsidized by the state, e.g. by adopting the Beveridge model for the 
organization of the healthcare system, as done in Denmark[11].  
The issues with the welfare economist approach to evaluation in healthcare has 
spurred the development of extra-welfarism[11]. The extra-welfarist approach is not 
exclusively used in healthcare[47], but in the present dissertation it is discussed only 
in this context. In recognition of the fact that market forces fail in the healthcare 
system, these are disregarded in the extra-welfarist approach to evaluation[11]. 
Nonetheless, extra-welfarism adopts the same main objective for actions in healthcare 
as welfare economics, i.e. the pursuit of increasing a maximand within budgetary 
constraints. One of the principal differences between welfare economics and extra-
welfarism is the notion of what should be maximized.  
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In the extra-welfarist approach to evaluation, observance of the normative key tenets 
comprising the cornerstones for the framework for welfare economist evaluation is 
relaxed (Box 1). To accommodate, amongst others, the criticism expressed by Sen, 
under extra-welfarism, outcomes other than individual utility may be used in 
evaluations[45,47]. In the most pragmatic approach to extra-welfarist evaluation, 
health constitutes the maximand and distribuendum of the healthcare system, which 
is in immediate agreement with the primary objective of the healthcare system, i.e. 
health maximization[13,43,45]. This implies that under extra-welfarism, health is 
considered to have intrinsic value, i.e. the value is not determined by the potential 
utility that it may entail for the individual. For this reason, health and elements that 
affect health status are often used as maximand in extra-welfarist 
evaluation.[13,43,47] In agreement with the welfare economist approach (cf. tenet III, 
Box 1), under extra-welfarism, the value of interventions is only determined by their 
expected final impact on health and not by the process, i.e. intervention such as 
surgery or medical treatment through which health maximization is achieved. This is 
consistent with the expectation that policymakers and patients do not seek medical 
care per se, but the health benefit that it conveys[11].  
Accepting health and elements that affect health as maximand for evaluation under 
extra-welfarism challenges the expectation of individual sovereignty in the welfare 
economist framework for evaluation (Box 1). Due to incomplete knowledge of the 
expected health value of different healthcare interventions, the individual may not be 
the best judge of how to achieve the highest level of health and may consequently not 
be able to give rational preferences to different healthcare interventions. Furthermore, 
under extra-welfarism, preferences for, for example, different health statuses may be 
derived from sources other than the individual who experiences the health state, such 
as samples representing the general population. The use of societal preferences 
towards health statuses can be justified by considering that decision-makers in 
publicly funded healthcare systems should safeguard their ‘stakeholders’’ interests; 
i.e. the society that subsidizes the healthcare system. Hence, it follows that by 
valuating outcomes by societal preferences, consistency between payer and payer 
preference is achieved. Application of pre-specified, transferable preferences for 
health states facilitates interpersonal comparability of outcomes. This enables 
comparison of the expected benefit of changes in health states irrespective of the 
individual achieving it, which would not be permitted under the welfare economist 
approach.[45,47]  
Despite the discrepancies between the welfare economist and extra-welfarist 
approaches to evaluation, extra-welfarism is still considered a subspecies of normative 
welfare economics[47]. Although the primary aim of the healthcare system is to 
improve health when possible, there are additional social and societal concerns that 
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are not explicitly incorporated in the pursuit of achieving Pareto efficiency, i.e. either 
under the welfare economist or the extra-welfarist approach[43,47]. This includes 
concerns of, for example, equal access to healthcare and the provision of high-quality 
care for all individuals. Sen directed a sharp critique of considering the Pareto 
optimum as a representation of the optimal allocation of resources, as Pareto 
optimality may be achieved in situations of high inequity and inequality, where 
resource allocation is highly skewed with some individuals receiving all resources and 
others none. By all other ethical standards, this would represent a suboptimal resource 
distribution.[47] Equity and equality concerns are explicitly incorporated into the 
stated aim of the healthcare system, i.e. in the Danish Health Care Act[43], which 
causes the rejection of a strict welfare economist approach to resource allocation in 
real-life policymaking.[47]  
Nonetheless, evaluation methods based on the extra-welfarist approach to evaluation, 
such as economic evaluation, are suitable for informing decisions in healthcare due to 
the common foundation and purpose of the healthcare system and the aim of extra-
welfarism. With its foundation in normative welfare economics, economic evaluation 
can be used to inform on – if not ensure – efficient use of resources.[13] 
 
3.3. ECONOMIC	EVALUATION	AS	A	DECISION	AID	FOR		
HEALTHCARE	PRIORITIZATION	
The purpose of economic evaluation is to inform on whether the amount of extra 
health benefit that healthcare interventions provide justifies the additional costs 
related to the interventions.[13] The existence of budgetary constraints and the need 
to contain costs emphasize the prudence of applying these methods to inform policy 
decisions in healthcare.  
In full economic evaluation, both the costs and consequences of interventions are 
considered to enable evaluation of the expected, i.e. average, incremental cost related 
to acquiring an extra unit of the effect measure, i.e. health benefit related to the 
interventions. Usually, the results of economic evaluations are presented via the 
incremental cost-effectiveness ratio (ICER)[13]: 
∆
∆
 
	 	 	 	 	 	 , . . 	  
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There is an inherent expectation in the evaluation tradition that new medical 
technology (designated A in the equation and in the incremental cost-effectiveness 
plane in Figure 3-1) provides a higher level of health benefit than the existing 
technology (designated B in the equation and in the incremental cost-effectiveness 
plane). If a course of actions, intervention A, provides positive incremental effects 
and negative incremental costs compared to intervention B, it dominates its 
comparator and is situated in the southeast quadrant of the incremental cost-
effectiveness plane in Figure 3-1, and vice versa for the northwest quadrant. If both 
the incremental costs and effects of intervention A versus B are eitherpositive or 
negative, the ICER is situated in either the northeast or southwest quadrant, 
respectively. In that case, the ICER may be compared to a cost-effectiveness 
threshold, i.e. a threshold for opportunity costs (λ) (Figure 3-1). In evaluations where 
dominance is not observed a threshold for opportunity costs is necessary to enable the 
interpretation and establishment of cost-effectiveness of the investigated 
interventions. Otherwise, the economic evaluation only provides information on the 
expected costs and effects of interventions, and cannot inform on the comparative 
value for money of the interventions.[13]  
The threshold for opportunity costs reflects the monetary value that society attaches 
to one unit of the chosen effect measure and is specific for that effect measure. The 
threshold represents the shadow price of the budget constraint, that is, the benefits and 
 
Figure 3-1. The incremental cost-effectiveness plane given intervention A vs. 
intervention B. λ represents the threshold for opportunity costs. ΔC: incremental 
cost, ΔE: incremental effect. 
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costs alike that are displaced if the intervention under investigation is adopted. For 
instance, for the effect measure quality-adjusted life year (QALY), the National 
Institute for Health and Care Excellence under the National Health Service in the 
United Kingdom has stated a threshold of £20,000–£30,000 per QALY[48]. Hence, 
for each £20,000 that are spent on healthcare resources in one clinical area, one QALY 
is displaced elsewhere in the healthcare system if no further resources are brought into 
the healthcare budget. This implies that if the ICER of intervention A vs. intervention 
B is above the threshold (Figure 3-1), the additional benefit provided by intervention 
A is smaller than the benefit that is displaced elsewhere in the healthcare system. This 
causes inefficient allocation of resources. Likewise, if the ICER related to the 
intervention under investigation is below the threshold, more than one unit of effect, 
e.g. QALY, can be achieved at the threshold value.[13]  
Opportunity costs will always occur under budgetary constraints, as the allocation of 
resources to one area obstructs the use of the same resources in another area. What is 
of interest is whether the benefit achieved by an allocation supersedes the benefit that 
could have been achieved elsewhere. The extra-welfarist decision rule of cost-
effectiveness provides that if the ICER is lower than the threshold, the course of action 
under investigation is considered cost-effective and should be accepted, whereas if it 
supersedes λ, it is considered cost-ineffective and should be rejected. Thus, the 
threshold reflects the maximum that the healthcare system, i.e. society, should be 
willing to pay for further benefit in order to avoid inefficient resource 
allocation.[13,14] 
 Despite its widespread use, the ICER framework suffers from deficiencies. It is not 
suitable for when incremental effectiveness approximates zero nor is it possible to 
generate apprehensible ICER intervals to evaluate possible dispersion of cost-
effectiveness estimates[13,49]. However, when a threshold for opportunity costs 
exists, the ICER and the decision rule for cost-effectiveness may be rearranged as: 
⟺
∆
∆
⟺ ∆ ∆ ⟺		
∆ ∆ 0. 
This is known as the net benefit (NB) framework, in which  ∆ ∆  is the 
incremental NB. If interventions are cost-effective, based on an established λ, the 
incremental NB is positive. The NB framework amongst other things, allows for 
evaluation of the uncertainty surrounding the cost-effectiveness of interventions, as it 
may be described via a distribution.[13,49,50]  
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If applying a strict extra-welfarist approach, the decision rule means that if a course 
of actions provides a negative incremental NB, it should not be adopted[11,46]. The 
threshold introduces a social commitment where all resources cannot be allocated to 
a particular intervention if the opportunity costs are considered too substantial. 
Economic evaluation may be used to illustrate the potential opportunity costs related 
to the introduction of interventions and help making prioritization explicit regarding 
the acceptance or rejection of interventions based on their expected costs, health 
benefits, and potential opportunity costs. The full economic evaluations include the 
cost-benefit analysis (CBA), cost-effectiveness analysis (CEA), and cost-utility 
analysis (CUA), which is sometimes recognized as a subspecies of CEA. Common 
among the evaluation types are the methods for accounting costs, which in all analyses 
are represented in monetary units. What differs is the chosen measure of effect.[13,14] 
 
3.3.1. OUTCOMES	IN	ECONOMIC	EVALUATION	
The effect measures used in extra-welfarist evaluation usually include indicators of 
well-being and measures of health as these reflect the main priority of policymakers 
within healthcare, whom the analyses are intended to inform.[13,43,47] 
CBA is closer associated with traditional welfare economics than CEA and CUA as 
the main purpose of CBA is to identify interventions that increase welfare, and not 
specifically health. Thus, in CBA health is not employed as the sole maximand. In 
CBA, health benefits are considered a commodity, whose value may be estimated 
based on the equivalent amount of consumption of other goods that individuals might 
otherwise have. Hence, the health benefits of interventions are established in monetary 
units, based on individuals’ preferences towards them, i.e. the monetary value that 
each individual attaches to the benefit. Commoditizing and monetizing health and 
health gain enables comparison of the benefits of interventions across different 
sectors. Consequently, the budgetary constraints that would normally apply to 
consumption of resources within the healthcare system are relaxed and CBA can be 
used to identify the allocation of resources that provides the greatest amount of total 
social welfare irrespective of sector origin.[11,13] There are, however, challenges 
involved in asking individuals to state their preferences towards, commoditizing, and 
monetizing health and interventions to increase health[11,13,46]. These challenges 
compose substantial obstacles for the application of CBA to health and healthcare. 
CBA remains the least used type of economic evaluation in healthcare[11,51].  
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In contrast to CBA, the methods of CEA and CUA have a stronger foundation in extra-
welfarism, recognizing of the failure of the market forces in the healthcare system. In 
CEA and CUA the budgetary constraints of the healthcare system are sustained. These 
form the restrictions under which CEA and CUA may be used to identify efficient 
allocation of resources.[13,45,46] Due to the limited use of the CBA in evaluations of 
healthcare [11,51], in this remainder of the present dissertation the term economic 
evaluation will refer to CEA and CUA only. 
The effect outcomes employed in CEA are measured in countable, natural units, 
which are expected to eventually affect health (see Box 2 for exemplification of 
CEA[52]).  Effect measures could include life years gained by increased survival, a 
decrease in the risk of ischemic stroke in AF, or the number of days with an adequate 
level of quality in anticoagulant therapy[13,52]. These effect measures immediately 
meet the criteria for extra-welfarist evaluation outcomes as they are expected to 
ultimately affect health. However, their application gives rise to some challenges with 
respect to the interpretation of analyses. Application of disease- or treatment-specific 
effect measures obstructs the comparison of interventions that do not have identical 
purposes and, therefore, dissimilar effect measures, or even if a similar effect measure 
is defined slightly differently in studies, resulting in incomparable evidence. This 
complicates the identification of efficient resource allocation across clinical areas and 
thus oppose the fundamental purpose of economic evaluation. Furthermore, as the 
purpose of the economic evaluation is to inform on the optimal decision in order to 
improve health within budgetary constraints, the application of a one-dimensional 
effect measure may potentially be misleading if the chosen effect measure does not 
contain all impact on health. For many diseases and treatments, the application of a 
single effect measure, such as improved survival achieved through therapy, would 
lead to incomplete evaluation of health benefit, as health is likely to be affected by 
multiple aspects of treatment simultaneously. Lastly, thresholds for opportunity costs 
are not established for the vast majority of clinical effect measures, which renders the 
results of CEAs with nondominance uninterpretable.[11,13,52] 
Effect measures for CEA also include clinical intermediate endpoints, such as changes 
in blood pressure, the level of serum cholesterol, etc. These may be applied as 
surrogates of final, patient-relevant outcomes. Their application may be justified if 
they are known to be predictors of patient-relevant outcomes that are known to affect 
health. Their application may be accepted if unreasonably long follow-ups or 
unrealistically large patient samples were required to observe direct impact on health. 
Changes in clinical intermediate endpoints do, however, not hold intrinsic health-
related value and are thus not optimal outcome measures in economic evaluation. 
Their direct application as outcome measures in CEA may lead to uninterpretable or 
misleading analyses and results. Instead, there must be a link between the clinical, 
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intermediate endpoints and final, patient-relevant outcomes, which enables modeling 
of changes in final impact on health (cf. section 3.4 for elaboration).[13,53] 
The WHO definition of health[44] provides the foundation for research in health-
related quality of life (HRQoL), which conceptualizes the effect measure in CUA.[11] 
Hence, the results of CUA may best inform decision-makers within the healthcare 
system, as the outcome most succinctly reflect the maximand of the healthcare system. 
According to the WHO definition, health is multidimensional and comprises more 
than the physical dimension of health, namely mental and social well-being, which 
should be taken into account to fully appreciate the impact on HRQoL provided by 
interventions.[11,44] The functional capacity, i.e. the ability to perform usual every-
day activities and the behavior that the functional capacity enables, is often equated 
with quality of life, where HRQoL refers to the functional capability that is contingent 
on health[54]. As the majority of the population suffers from one or more chronic 
diseases[6], the functional capacity that individuals experience, despite the presence 
of disease, becomes increasingly more important than, for example, survival.[11]  
 
A generally accepted – though not globally implemented – generic measure of 
HRQoL is the QALY. The use of QALY as an effect measure operationalizes HRQoL 
and enables summary valuation of both the expected quality and the quantity of the 
life lived, i.e. morbidity and mortality, respectively, into a single index measure. This 
enables evaluation of interventions that may affect the quality and quantity of life 
simultaneously and potential trade-offs between gains in quality and quantity of life. 
The application of QALY as an effect measure of health benefit allows for comparison 
Claes et al.[52] performed a CEA to evaluate the costs related to increasing 
quality in warfarin therapy by four different quality-improving initiatives in 
general practice, which targeted the organizational model for management of 
OAC. Cost-effectiveness results were expressed as the incremental cost per extra 
day in which therapy was considered within the therapeutic range (cf. section 
4.1.2 for elaboration). Claes et al. found that multifaceted education and the use 
of decision-assisting equipment dominated the previous organizational 
management model for OAC in general practice by improving the quality of 
therapy at a lower cost.[52] 
However, if incremental costs and effect had been positive (or negative), it would 
have been impossible to evaluate the cost-effectiveness of the intervention as no 
threshold for the applied effect measure is available and the health-related value 
of more days with therapy within the therapeutic range is vague. This illustrates 
the difficulties of interpreting the results of CEA when dominance is lacking. 
Box 2. Exemplification of a cost-effectiveness analysis by Claes et al.[52]. 
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of diseases and interventions across different clinical areas by ‘translating’ their 
impact on, for example, mortality and the occurrence of final, patient-related 
outcomes, such as stroke, myocardial infarction, etc., into impact on the single-unit 
measure. Hence, CUA meets the aim of economic evaluation of providing information 
on efficient allocation of resources within the entire healthcare system and not just a 
specific clinical area. By employing a single-unit measure to embrace all impact on 
health, the application of one threshold for opportunity costs is enabled. [13,14,49] 
Currently, in Denmark, there is no recognized threshold for opportunity costs for 
QALYs. For this reason, a threshold equal to £20,000–£30,000 per QALY[48] is often 
assumed. 
When operationalizing HRQoL through the use of the QALY, different health states 
may be ordered according to their desirability, i.e. the QALY weight that is attached 
to them. The weights are generally ordered in relation to two health states, ‘perfect 
health’ and death, which comprise the reference points for setting the QALY weights 
of further health states. Normally, the maximum QALY weight that may be attached 
to a health state is 1, which equals perfect health. Hence, a year in the ‘perfect health’ 
state would yield one QALY. The corresponding QALY weight of death is set to 0 
and, consequently, irrespective of the time spent in that health state, the accumulating 
QALYs would be zero, which is intuitively correct. The QALY weights that are 
attached to health states should be based on preferences, under the expectation that 
better health states are given higher preferences, which is consistent with the 
maximization approach in normative health economics. Any conditions or events 
befalling an individual that worsen the ‘perfect health’ state, such as disease or 
treatment complications, would lower the preferences for that health state, which 
would consequently be given a lower QALY weight. This would subsequently affect 
the accumulation of health benefit, i.e. QALYs, when individuals experience the 
health state over time. In disagreement with the welfare economist approach (cf. Box 
1), the preferences for health states may be elicited from representatives of the general 
public and not only individuals experiencing the specific health states. Valuation and 
comparison of health states across individuals is thus enabled by the application of 
preference weights for the health states, elicited from the population rather than the 
individuals.[13,45,47]  
Although use of the QALY ensures comparison of the effectiveness of interventions 
across different therapeutic fields and the setting of a single threshold for opportunity 
costs, it is still a disputed effect measure. The estimation and utilization of QALYs is 
enabled by a number of assumptions, whose bearing in real life is debatable[13,45]. 
One of the main assumptions concerns the rationality of decision-makers. Individuals 
are expected to demonstrate rational, risk-neutral, and consistent preferences towards 
health states[11,45]. For instance, a QALY should hold the same value, irrespective 
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of the therapeutic field in which it is obtained. Thus, increasing the HRQoL from a 
weighting of 0.2 to 0.4 should be equal to increasing the weighting from 0.8 to 1.0, 
based on an interval scaling of the QALY weights. This may not represent real-life 
preferences, as society may prefer to help those in poor health (QALY weight 0.2) to 
achieve a better HRQoL than those in relatively good health (QALY weight 0.8) to 
obtain perfect health. In addition, the assumption of rational decision-making requires 
a certain ‘time independence’ of the QALY weighting. Hence, a QALY should hold 
the same value irrespective of the age at which it is obtained, which may not reflect 
the opinion of society. Also, the QALY weight of health states should be independent 
of the duration of time, in which individuals are expected to experience the health 
state. The required preference consistency may thus be violated in real life as ‘a 
QALY is not necessarily a QALY’ in the eyes of the population whose preferences 
decision-makers should safeguard when prioritization is made.[13,45,46]  
Simple aggregation of QALYs may therefore not be consistent with the normative 
purpose of maximizing the benefit to society, as the aggregated QALYs may not 
necessarily hold social value. Furthermore, the QALY has a rather narrow focus by 
only embracing impact on health-related quality of life[54]. The QALY has been 
criticized for not including other aspects that might equally affect individuals’ quality 
of life, such as their perceptions and satisfaction with the convenience of care, etc. 
(insofar as these elements are not reflected in the QALY weights resulting from 
disease and treatment).[13] Consequently, it has been argued that use of the QALY 
does not necessarily reflect individuals’ true, resulting capacity when such aspects are 
not explicitly included in evaluation. As a counterargument, it may be stated that the 
QALY is a pragmatic, reasonable, and operable approximation of the explicated 
maximand in the healthcare system, i.e. health, which is the primary concern of the 
policymakers, whom the analyses are intended to inform. As individuals’ capability 
is contingent on the existence of a reasonable level of health, it has been argued that 
the QALY therefore provides a reasonable approximation of the expected capability 
of individuals.[13,46,47] Despite the perhaps insufficient reflection of true social 
value of the QALY, its development is still founded in extra-welfarism. Consequently, 
its use reflects the underlying utilitarian ethics and philosophy of normative health 
economics and reflects an efficiency-maximizing approach to decision-making. 
Utilitarianism and the ethical considerations that it represents remain disputed as a 
foundation for resource allocation, as “an economy can be Pareto optimal, yet still 
perfectly disgusting by any standards”[47]. CUA and QALY are accordingly subject 
to the same critique[11,46,47]. 
Despite the criticism of the QALY, CUA nonetheless is currently the preferred type 
of economic evaluation in healthcare and is increasingly applied.[45,51,55] 
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3.3.2. THE	SCIENCE	AND	ART	OF	EVIDENCE‐BASED	MEDICINE	
As health economics revolves around health and healthcare, the methods for economic 
evaluation have, to a large degree, evolved in accordance with the views and 
approaches seen in research in medicine, specifically evidence-based medicine 
(EBM). EBM is characterized by a rigorous approach to the design and interpretation 
of studies, with a strong focus on determining the potential causality between 
interventions and outcomes and statistical inference. Accordingly, the methods for 
economic evaluation have been developed to embrace the challenges and 
epistemological views that apply to EBM. As a result, evidence on particularly 
outcomes in CEA and CUA often derives from research in medicine.[11,24,56]  
When the concept of the RCT was established in the 1980s, formal evaluation of new 
medical technology prior to its introduction became a reality. Since then, evidence of 
the effect and safety of medical technology is increasingly requested prior to its 
application in real-life practice.[14,26] In EBM, the RCT is regarded as the optimal 
design for evaluating the effect of interventions when the purpose is to investigate 
possible causal relationships between interventions and expected outcomes. The RCT 
design allows evaluation of the effect of interventions in a counterfactual, controlled 
environment, thereby enabling detection of the ‘true’ effect of interventions, in theory 
unaffected by other influencing factors. Hence, it is used to evaluate the relative safety 
and effect of one intervention, ceteris paribus, versus a comparator[39–42,57].  
The RCT design is optimized for the evaluation of potential causality between a single 
or few determining factors and a limited number of outcomes.[26,56] The estimate of 
effect from clinical trials is referred to as the efficacy of interventions, which 
comprises the ‘technical frontier’, i.e. the maximum benefit from interventions that 
may be achieved under ideal circumstances[23,56]. By design, efficacy data may not 
hold the influence of other important non-medical factors that influence the effect of 
interventions outside the controlled trial environment[23,56]. Hence, when efficacy 
data are used to inform on the cost-effectiveness of interventions, the results may not 
reflect what will be observed in real life. This may especially apply, if the quality in 
within-trial therapy and in real-life practice differs or if trial populations are not 
representative of the patients treated in practice. Consequently, data on effectiveness 
rather than efficacy would, theoretically, constitute the better data grounds for 
economic evaluation when the purpose is to provide information on the expected NB 
of interventions in real life.[13] 
EBM has been developed with the purpose of supporting clinical decision-making. In 
contrast, economic evaluation is to a high degree intended to support healthcare 
CHAPTER 3.  
METHODOLOGY 
23 
prioritization and policymaking. In decision-making in clinical practice, decision-
makers handle tangible decision problems concerning specific patients, whereas in 
policymaking, the individuals whom decisions concern are ‘faceless.’ Social decisions 
require empathy, but also a certain degree of detachment to provide decisions that are 
optimal for the common good and should therefore not be founded on the grounds of 
single, clinical cases. Consequently, policy decisions should be made based on what 
on average comprises the optimal solution. This may not be consistent with what 
constitutes the optimal solution in a specific clinical situation, for which reason the 
two decision contexts cannot be equated.[11,13] 
 
3.3.3. WHAT	YOU	ASK	IS	WHAT	YOU	GET		
–	THE	IMPORTANCE	OF	STUDY	DESIGN	
Under extra-welfarism, the design of the economic evaluation should be contingent 
on and reflect the decision context, in which it is used. As such, the result of an 
economic evaluation differs depending on the question that it is to answer[47].  
Often economic analysis comprises only a few, often only two, comparators. Of these, 
the currently used intervention or gold standard should be represented to ensure that 
the NB of new technology is compared to the NB of a realistic, otherwise used course 
of actions. Ideally, however, all relevant comparators for a specific decision problem 
should be compared to ensure full disclosure of the comparative cost-effectiveness of 
relevant interventions[13]. The applied perspective in an economic evaluation 
determines the costs that are included in the analysis and should be relevant to the 
decision-maker whom it is intended to inform. The broadest – and most demanding 
to the analyst – perspective is the societal perspective, in which all costs should be 
included, irrespective of who defrays them. When a narrower perspective than the 
societal one, e.g. a healthcare sector or hospital perspective, is applied, the cost 
analysis does not necessarily reflect the true cost to society if other payers outside the 
scope of the analysis defray the cost. In Denmark, the societal perspective is 
recommended as first choice to avoid fallible conclusions regarding the true cost-
effectiveness of interventions.[13,14,58] Likewise, economic evaluation should 
include all incremental costs and effects, irrespective of their temporal occurrence, to 
avoid under- or overestimation of the cost-effectiveness of interventions. For 
interventions that have a long-term impact on health and cost accumulation, e.g. by 
increasing survival or decreasing a continuous risk of debilitating complications for 
treated patients, the appropriate time horizon for the evaluation of costs and effects 
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would potentially be patients’ lifetime. This is generally the case for treatment of 
chronic diseases.[13] 
These requirements immediately highlight the problems with using, for example, an 
RCT as the sole source of evidence on which to build a sound economic evaluation. 
Thus, clinical trials often fall short of including all relevant comparators, they often 
cannot capture all relevant impact on health and costs due to a different focus and a 
restricted follow-up and may combine clinical events into aggregate outcomes that 
become uninformative regarding the appertaining costs and impact on 
HRQoL[14,56]. This should not be considered a failing of EBM but illustrates that 
the discipline was not developed with the aim of informing policy decisions. To 
facilitate sound economic evaluation, it may therefore be necessary to compile 
evidence from multiple sources and to extrapolate data beyond the available 
evidence[13,14]. Decision-analytic modeling (DAM) provides the means of doing 
so[13,49]. 
 
3.4. DECISION‐ANALYTIC	MODELING	–	A	TOOL	TO	AID		
DECISION‐MAKING	UNDER	UNCERTAINTY	
DAM is a tool developed upon the principles of statistical decision theory and 
Bayesian decision analysis and provides a systematic approach to decision-making 
under conditions of uncertainty[49,59,60]. DAM has its roots in welfare theory and 
was developed with the explicit purpose of supporting decision-making and 
prioritization when resources are scarce. DAM is used to identify the optimal 
alternative included in the economic evaluation, e.g. by identifying whether an 
intervention is expected to be cost-effective compared to the gold standard. As a 
vehicle for economic evaluation, DAM enables many of the requisites of a sound 
economic evaluation. It enables comparison of all relevant comparators, inclusion of 
all relevant impact on health and costs by allowing relevant evidence to be compiled 
from multiple sources, and extrapolation of clinical data beyond their observation to 
reflect an appropriate time horizon. In DAM, a model is built in which all relevant 
elements are included systematically to reflect the decision problem at hand. A model 
is composed of a set of mathematical relationships between the entities that constitute 
the alternatives under investigation. The use of mathematical relationships between 
the entities enables, amongst other things, the linking of clinical, intermediate 
endpoints to patient-relevant outcomes and the linking of patient-relevant outcomes 
to expected impact on HRQoL.[13,49,60]  
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The results from DAM are based on expected values of the different alternatives under 
investigation. In the models, the consequences of the alternatives, i.e. events occurring 
and both their potential impact on health and costs, are contingent on the probability 
of the events occurring. Thus, the expected values of the different decision options in 
a model are contingent on the consequences of the events included in the model 
multiplied by the probability of the events occurring. It follows that the expected 
values reflect the mean values of effects and costs of the different decision options. 
Decision-analytic models present simplifications of the alternatives and their impact 
that would be expected in the real world. Construction of the models requires explicit 
decisions regarding the inclusion of expectedly essential elements in the model – and 
exclusion of elements that are expected to not affect the results and hence are 
irrelevant in the decision-making context.[13,49,60]  
The different parameters included in a decision-analytic model, including cost, effect, 
and probability parameters, may be included as distributions reflecting the uncertainty 
pertaining to them. The impact of these uncertainties may be included and investigated 
in sensitivity analyses. Hence, DAM enables the identification of what, on average 
and based on the included evidence, constitutes the most efficient alternative. 
Furthermore, DAM entails an explicit acceptance that decisions must be made under 
uncertainty and actively enables the incorporation and evaluation of the uncertainty 
that pertains to the utilized evidence and how it may affect decision uncertainty. In 
addition, via the construction of the decision-analytic model and retrieval of evidence 
to populate it, any gaps in current evidence and highly uncertain parameters may be 
highlighted.[13,49]  
 
3.4.1. BAYESIAN	DECISION	THEORETIC	APPROACH	TO	DECISION‐MAKING	
Irrespective of the origin of the evidence used in economic evaluation, some degree 
of uncertainty always pertains to it. As such, decisions must be made under conditions 
of uncertainty, which introduces the risk of making suboptimal decisions. Making the 
‘wrong’ decision would impose opportunity costs. Either because cost-effective 
therapy is detained and thus unavailable to patients who would otherwise have 
benefitted from it, or because cost-ineffective therapy is reimbursed, thereby 
decreasing the total health benefit that the total patient population might have 
achieved if the resources had been used elsewhere. Therefore, the risk of making the 
wrong decision carries a cost in itself.[14,49,50]  
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In a policy context, decisions should be made on the mean expected NB of 
interventions, irrespective of the uncertainty that pertains to the included 
evidence[13,50]. If applying the rules of classical statistical inference, any 
intervention demonstrating a positive, but not statistically significant incremental NB 
versus a relevant comparator should be rejected. However, as the mean incremental 
NB was positive, this rejection would impose opportunity costs. Thus, it has been 
argued that in a decision-making context, no particular attention should be paid to the 
level of statistical significance[26,49,50]. Although uncertainty, therefore, should not 
immediately affect the decision as to whether to adopt an intervention, it may still 
affect the decision-making process. If the evidence base for an evaluation is 
insufficient or of poor quality, the validity of any evaluation relying on it may be 
disputed. Applying a Bayesian decision theoretic approach to decision-making, two 
conceptually different decision questions present themselves in the decision-making 
process that should be distinguished from each other. The first  question of whether 
to adopt an intervention, given the existing evidence should be distinguished from the 
second question of whether further evidence should be requested to reduce the 
uncertainty that pertains to the included evidence.[49,50,59] The latter might be the 
case if the evidence substantiating the evaluation is considered to be too uncertain.  
DAM may be utilized to evaluate the uncertainty that pertains to the different 
parameters included in a model and how it may affect the certainty of cost-
effectiveness of the interventions under investigation and, consequently, the validity 
of the evaluation results. The individual parameters may be included in the model by 
using appropriate distributions that reflect the uncertainty applying to them. 
Probabilistic sensitivity analysis (PSA) may subsequently be used to evaluate all 
parameter uncertainty simultaneously and how it affects the decision uncertainty. In 
PSA, repeated sampling from the included parameter uncertainty distributions 
generates a NB distribution of interventions, typically consisting of 10,000 individual 
NB estimates. PSA may be used to indicate the probability that the optimal decision, 
as established via the expected values in the model, is, in fact, the optimal decision 
when taking into account the combined parameter uncertainty in the model. If the 
optimality of the decision is highly uncertain based on the current level of evidence, 
it might be considered whether further evidence should be requested to decrease the 
risk of making the ‘wrong’ decision. That is, recommending interventions that, in fact, 
have a negative incremental NB compared to their comparator. As the combined 
parameter uncertainty affects the decision uncertainty, the presence of poor-quality 
evidence increases the risk of making suboptimal decisions.[13,49,59] The potential 
cost of uncertainty, i.e. the potential cost of making the wrong decision due to existing 
uncertainty, constitutes a ‘payer uncertainty burden;’ the burden that the payer and 
decision-maker must carry if their decision is wrong. 
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From a decision-oriented view, the uncertainty that revolves around particular 
parameters is only of interest if it is able to change the decision that would otherwise 
be made, based on the expected values from the analysis. Consequently, sufficient 
evidence is not necessarily perfect evidence. Parameters may be highly uncertain, but 
not necessarily affect the decision uncertainty, for which reason their uncertainty is 
inconsequential to the decision and therefore – from a decision-oriented viewpoint – 
unimportant.[49,50,61]  
The evidence base may be improved by acquiring further information via, for 
instance, further research. It is not possible to eradicate all uncertainty, though; some 
will always remain[14,49]. Conducting studies to generate more evidence draws on 
limited resources; if more precise estimates of a parameter are not expected to affect 
the decision uncertainty substantially and thereby the decision, the execution of such 
studies would represent inefficient use of resources.[14,59,61] This highlights the 
potentials of identifying parameters that affect the decision uncertainty, and on which 
uncertain parameters it might be beneficial to procure information. Value-of-
information (VOI) analysis may be used for this purpose[59]. VOI analysis can be 
used to calculate the total cost of uncertainty related to all parameter uncertainty in a 
model, but also the cost of uncertainty pertaining to specific parameters in the model, 
via the expected value of perfect information and the expected value of perfect 
parameter information, respectively. These estimates may be used to evaluate the 
potential cost of uncertainty of specific parameters and, consequently, determine the 
amount of resources that maximally might be allocated to eradicate the 
uncertainty.[49,60] The use of VOI analysis is further elaborated on in the paper 
presented in Appendix A.	 	
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3.5. QUALITY	IMPROVEMENT	IN	THE	HEALTHCARE	SYSTEM	
To enable the evaluation of quality improvement, it is necessary to generate a 
consensus about what may be understood by the concept of ‘quality’ and quality 
improvement and subsequently how it may be evaluated. Consequently, the purpose 
of the presentation in this section is not to delve into the intricacies and challenges in 
quality evaluation and improvement in practice, but only outline the concepts that 
comprise the foundation for the majority of research in quality in healthcare.  
 
3.5.1. THE	ELEMENTS	OF	QUALITY	
The foundation of modern quality evaluation is often ascribed to the physician Avedis 
Donabedian. In the 1950s, Donabedian developed a conceptual model that provides a 
framework for the assessment of quality and quality improvement in healthcare. In 
the Donabedian framework, no definition is supplied as to what ‘quality’ in healthcare 
actually comprises, but it may ambiguously be said to be a reflection of the values and 
purposes of the medical care system and, on a larger scale, the society as a whole.[23] 
In this interpretation, the focal point of quality in healthcare is the health of patients 
and the population as a whole[23,43], but it also implies that quality in healthcare 
entails other aspects of healthcare delivery. In the Donabedian framework certain 
attributes of quality are attached to healthcare interventions that can be used to 
evaluate their quality (Box 3)[24,62]. The attributes pertain to different aspects of 
healthcare delivery and simultaneous consideration of these is required to achieve a 
thorough evaluation of the quality of healthcare interventions. As they represent 
elements of quality, it is desirable to improve the attributes, which makes them objects 
for quality improvement. Evidently, some of the attributes are synergistic. However, 
some are also contradictory and their individual importance should therefore be 
considered and weighted when interventions are evaluated.[62]  
What is perceived as quality in different situations may differ, and hence a uniform 
definition and evaluation of the quality of healthcare across interventions is precluded 
under the Donabedian model. The lack of a clear, specific definition of quality in the 
Donabedian framework for assessment of quality and quality improvement is both a 
strength and a weakness. It does not confine the use of the model to evaluations where 
a certain interpretation of the concept of quality is applied, but it also carries the risk 
that interpretation and subsequent measurement and comparison of quality in different 
decision contexts are hampered.[24,62]  
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In the Donabedian model, three dimensions of quality are furthermore presented to 
ease classification of information on the quality of interventions and, hence, 
evaluation. These dimensions – and associated classifications –  are structure, 
process, and outcome.[23,24] In this conceptualization, the dimension structure refers 
to the system characteristics that form the structural and organizational framework of 
a setting. Structure encompasses the attributes of the setting, including the available 
conditions and resources that restrict and determine the ability of the system to meet 
 Efficacy  The effect of an intervention under optimal circumstances. The 
efficacy of an intervention constitutes the technological frontier, i.e. the maximal 
improvement that may be expected from the intervention given specific 
circumstances and patients’ characteristics. 
Effectiveness The observed effect of the an intervention under real-life 
circumstances as experienced in daily practice, i.e. the degree to which the 
demonstrated efficacy may be achieved under conditions of, potentially, alternate 
quality levels. 
Efficiency A measure of the cost that is required to gain improvement 
through the intervention. If more interventions with the same gain are compared, 
the intervention with the lowest cost is the more efficient. 
Optimality When the value of the improvement of interventions is compared 
to the costs related to gaining it. At the optimum, the cost related to gaining 
improvement is at the lowest. With optimality, the concept is introduced that the 
marginal value of increasing quality may by counterbalanced by the costs 
required to gain the value, potentially rendering the costs related to a quality 
improvement unreasonably high. 
Acceptability Patients’ subjective valuation of effectiveness, efficacy, and 
optimality, but also of their experience and preferences regarding the physician-
patient relationship, accessibility of care, etc. 
Legitimacy The acceptance of the society of interventions. Legitimacy may 
differ from individual patients’ acceptability, as it concerns the welfare of the 
collectivity, which may be different from the desires of the individual. 
Equity The just distribution of healthcare to the members of the 
population. That is what is considered acceptable to the individuals of society, 
but also legitimate to the society as a whole. Equitable distribution of healthcare 
may consequently not necessarily be the most cost-effective. 
Box 3. Attributes of quality of healthcare as described for the Donabedian 
framework[62]. 
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healthcare needs. Thus, structure includes the organizational preconditions of 
healthcare provision, e.g. the organization of healthcare personnel and financial 
management, and physical surroundings – both material resources, such as facilities 
and equipment, and human resources, such as qualified personnel. Process refers to 
the activities – or services – that are carried out by healthcare personnel in the setting 
under evaluation. The process dimension, therefore, entails all clinical processes in 
relation to the continuity of care of patients, including diagnosis, therapy initiation, 
continuous care, rehabilitation, etc. Lastly, outcome refers to the effect of the 
intervention under evaluation on the health status of patients and the population. The 
health status is affected by changes in patients’ HRQoL, mortality, morbidity, 
complication rates, functional level, etc. With the application of a broader definition, 
changes in patient behavior, understanding, and satisfaction may also be included in 
the definition of outcome.[20,23,24] 
The three dimensions of quality in healthcare are often presented as a unidirectional 
causal chain (Figure 3-2), in which the quality of prior dimensions conditions the 
quality of later dimensions. Hence, the existence of suboptimal quality in, for instance, 
structural quality, e.g. available technical equipment, will be propagated through the 
model and obstruct the attainment of high quality in patient-relevant outcomes 
 
Figure 3-2. Dimensions of the concept of quality and examples of quality indicators 
that may inform on the quality of healthcare. Based on the Donabedian 
model.[20,24] 
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affecting health. Thus, the ultimate effect on health status is contingent on the 
preceding dimensions to be of sufficient quality. If deficiencies in a prior dimension 
are present, these will manifest themselves throughout the rest of the causal chain.[23] 
The three-part approach to classification of information on quality of healthcare may 
improve intelligibility when establishing the possible impact of changes in the 
different dimensions of quality on patient-relevant outcomes and health status. The 
Donabedian model remains a cornerstone in modern approaches to quality evaluation 
and improvement in practice. Today, it is the dominant paradigm for quality 
improvement assessment and research.[19,20] 
The influential American Institute of Medicine (IOM; now known as the National 
Academy of Medicine) has proposed a framework for quality improvement that is 
perhaps more workable than the conceptual model by Donabedian. In substance, the 
IOM framework is based on the Donabedian model. It does, however, include a more 
explicit definition of the concept of quality in healthcare.[63] Hence, the IOM has 
defined quality as “the degree to which health services for individuals and populations 
increase the likelihood of desired health outcomes and are consistent with current 
professional knowledge”[63]. In this definition, the focal point of quality in healthcare 
is the achievement of desirable health outcomes. This is in general agreement with the 
Donabedian definition[23], although the societal considerations related to quality of 
healthcare represented by the attributes ‘legitimacy’ and ‘equity’ in the Donabedian 
framework are deprioritized (Box 3)[63]. In 2001, the IOM adopted six constituent 
elements of quality that may be subject to improvement: safety, effectiveness, patient-
centeredness, timeliness, efficiency, and equity (Figure 3-3). With the IOM definition 
of quality in healthcare and the explication of the six aims for quality improvement, 
the IOM instigated a focus on what real-life quality improvement may entail, thereby 
providing a framework for quality improvement in practice.[63,64]  
In essence, most approaches to quality evaluation and improvement reflect similar 
interpretations of the concept of quality and entail more or less the same constituent 
elements as advanced in the Donabedian framework and the IOM conceptualization 
of quality in healthcare[20,62,63]. All approaches adopt health status – and 
satisfaction – as the focal component of quality in healthcare. Thus, it could be 
presumed that the ultimate purpose of quality improvements must be to improve the 
health of patients and the population, which is in line with the purpose of economic 
evaluation[23]. When appraising the applicability of economic evaluation to the area 
of quality improvement, the IOM aims for quality improvement can be used to aid 
contextualization[63]. Consequently, given an appropriate research design, economic 
evaluation accommodates the assessment of the elements of effectiveness, safety, 
efficiency, and timeliness, the outcomes of which may affect patients’ health status 
and/or satisfaction. In contrast, the most prevalent approaches to economic evaluation 
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do not explicitly include the elements equity and patient-centeredness in their 
methodological framework. Thus, it may be inferred that quality in healthcare is 
composed of more components and reflects a higher complexity than is traditionally 
embraced by the maximand used in economic evaluations. This discrepancy between 
the potential targets for quality improvements and what is used as maximand in 
economic evaluation should be deliberated when economic evaluation is considered 
for quality improvements. 
 
  
 
Figure 3-3. Constituent elements of quality and aims for quality improvement 
proposed by the Institute of Medicine[63,64]. 
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3.5.2. APPLICATION	OF	QUALITY	INDICATORS	FOR		
QUALITY	EVALUATION	
Quality and quality improvement in healthcare may be assessed by qualitative and 
quantitative methods, depending on the purpose of the assessment[19,23,24]. In the 
present dissertation, the focus is on the quantitative assessment of quality 
improvement, which requires instruments to facilitate measurement and evaluation of 
possible effects. QIs provide useful, quantitative measures for the evaluation of 
quality and any change achieved through improvements in care. QIs may be used for 
multiple purposes including documentation of care, benchmarking, priority setting, 
and evaluation of the effect of quality improvement.[20,23] The present dissertation 
focuses on the use of QIs as measures of quality improvement.  
Most definitions of QIs relate to the dimensions of quality presented in the 
Donabedian model and the information they provide is classified accordingly[20,24]. 
Structural QIs reflect preconditions that are conducive to healthcare provision; for 
instance, they may indicate the availability of clinical practice guidelines that are 
conducive for evidence-based therapy. Process QIs are used to assess healthcare 
delivery under the circumstances provided by the system characteristics, e.g. the 
proportion of patients treated according to clinical practice guidelines. Finally, 
outcome QIs may be used to evaluate the impact of healthcare on the health status of 
patients, for instance through the occurrence of patient-relevant outcomes, such as 
changes in the mortality or disability of patients.[20,24] Outcome QIs, furthermore, 
include intermediate indicators of biological functioning, i.e. biomarkers that are 
known to have longer-term effect on the health status of patients[20]. Evidently, there 
is consistency between the classification of outcome QIs and the preferred outcomes 
in EBM. Examples of QIs related to the different dimensions of quality are given in 
Figure 3-2.  
QIs may be employed with different objectives. Sentinel QIs indicate occurrences that 
are inherently undesirable, such as severe adverse events, and are used to flag 
incidents where the course of events leading up to the occurrence requires further 
scrutiny. In the present dissertation, however, the focus is on QIs used to evaluate the 
quality of everyday practice, i.e. related to events that occur with a certain frequency 
within the expectations of standard care. Ideal QIs are reproducible, measurable, 
generally accepted by practitioners and researchers, evidence-based, and outcome-
validated, i.e. the relationship between the QI and patient-relevant outcomes should 
be established[20,23]. Despite this, all QIs are to some degree sensitive to 
measurement error, which affects their validity. Greater uncertainty is introduced 
when subjective judgment is required to indicate quality. In particular, measurement 
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of process QIs may be susceptible to some degree of valuation and, therefore, be less 
stable than outcome QIs. For instance, for a process QI, e.g. “proportion of patients 
treated according to clinical practice guidelines,” a certain degree of interpretation 
may be required to assess whether sufficient adherence to the guidelines is 
demonstrated. In contrast, patient-relevant outcomes, such as mortality and rates of 
clearly defined complications, constitute unquestionable QIs of effectiveness and 
safety, for which impact on health cannot be disputed.[23] The request for objective 
measures of quality favors the use of estimable endpoints, which are less prone to 
valuation[20].  
When quality and quality improvement are evaluated by the use of QIs, the measures 
may be compared to quality standards, which may indicate aims that should be 
achieved for the quality to be considered acceptable. The standards should be 
evidence-based and derive from reliable sources. Their origin may be empirical or 
normative, where empirical standards derive from evidence on the level of quality in 
healthcare that may be attained in real-life practice. In contrast, normative standards 
are often agreed upon by experts in the therapeutic field, for which the standard is 
developed and may reflect levels of both acceptable and optimal care. Standards may 
furthermore be explicit and implicit. Explicit standards set a pre-specified quantitative 
aim that should be achieved for quality to be deemed acceptable, whereas implicit 
standards may be set for individual patients and be adapted to specific cases to adjust 
for factors that may affect the level of quality that may be realized.[20,23,24]  
To enable sensible and informative evaluation of interventions, the QI(s) that are 
applied should be sensitive to changes imposed by the intervention and should reflect 
the main purpose of the intervention[23,24]. For instance, if the purpose of a quality 
improvement were to enhance rehabilitation after ischemic stroke, mortality would be 
a poor choice of indicator of effectiveness. Accepting the basic assumption that the 
main purpose of the healthcare system and quality improvement is to improve and 
maintain health, the best QIs of effect would offhand be outcome QIs that impact 
patients’ health status directly[23]. However, for some quality improvements the 
application of patient-relevant outcomes as QIs would not be feasible due to them 
occurring only sporadically or after long follow-ups, or if only small patient 
populations were available for study, resulting in underpowered analyses.[20,24,27] 
For some interventions, structural or process QIs may be more sensitive to 
improvement caused by interventions and may, therefore, be favored to enable 
detection of statistically relevant changes. For instance, process QIs are more sensitive 
to improvements in the act of caring that may go undetected by an outcome QI 
because, within reasonable study implementations, the incidence of patient-relevant 
outcomes would be impacted by relatively little. In such cases, meaningful assessment 
of possible quality improvements through the use of outcome QIs would require 
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unreasonably large samples or follow-ups.[27] With the application of structural, 
process, and intermediate outcome QIs evidence on effect may be procured without 
delay[20,53]. The National Quality Measures Clearinghouse, which is an initiative of 
the Agency for Healthcare Research and Quality under the U.S. Department of Health 
and Human Services, holds more than 2000 evidence-based QIs available to the 
public[65]. More than 60 percent of the registered QIs are process QIs[66], which 
emphasizes the currency of the use of these QIs in research in quality 
improvement.[23]  
Structural and process QIs do not possess intrinsic value. They only signify quality if 
change in them ultimately reflects change in patient-relevant outcomes and health 
status.[23,67] Therefore, the relationship between QIs and the impact on health status 
should be validated prior to the application of the QIs for assessment of the quality in 
healthcare[20,24,67]. However, the evidence supporting the relationship between 
structure, process, and outcome is often sparse. Thus, there are QIs and standards used 
in practice that have not been outcome-validated (exemplified in Box 4)[67]. At best, 
the use of QIs and standards that has not been validated may lead to vague and 
questionable conclusions on the performance of interventions. At worst, their use may 
lead to erroneous conclusions on the benefit of interventions. 
If there are many antecedents between applied QIs and patient-relevant outcomes, it 
may affect the ability to establish causal inference between changes in the QI and 
changes in health status. Antecedents include explanatory factors for the elements 
under investigation and may include, for instance, the organization of continuity of 
care, the competencies of healthcare personnel, the doctor-patient relationship, patient 
and disease characteristics, etc.[20] As more antecedents may take effect with greater 
distance in the causal chain between the QI and patient-relevant outcomes, the 
distance may impede the establishment of causality. The same applies to the 
The interval between tests of international normalized ratio (INR) during warfarin 
therapy of vulnerable elders has been propounded as a process QI, with a 
maximum time interval of six weeks between tests representing the standard. 
However, the correlation between testing intervals and outcomes is only 
suspected, and not validated, and the six-week standard is not based on evidence 
suggesting that safety and effectiveness should be improved by this testing 
interval.[23,67]  
If accepting the premise that the main purpose of the healthcare system is to 
improve health, this QI and standard do not necessarily reflect quality in 
healthcare and may be erroneously applied.  
Box 4. Exemplification of the use of a non-validated quality indicator and quality 
standard within oral anticoagulant therapy[67]. 
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relationship between the intervention and expected change in the applied QI: If the QI 
may be affected by more antecedents, the attribution of effect to the intervention may 
be questioned (Figure 3-4). The existence of antecedents thus attenuates the causal 
inference between interventions and ultimate change in health status due to the 
antecedents. There is an inverse relationship between the distance between the 
intervention and patient-relevant outcomes and the ability to make causal inferences 
about the relationship between the intervention and ultimate health gain.[23] As a 
result, quality ‘improvements’ targeting the structural quality of healthcare are likely 
not to result in noticeable changes in patient-relevant outcomes within reasonable 
study setups[24]. The deployment of such interventions may therefore be disputed, if 
their impact on health cannot be established. This poses an objection to the sole use 
of patient-relevant outcomes for the evaluation of quality improvements as these will 
be influenced by all antecedents preceding their occurrence in the causal chain[27].  
Antecedents may be equally or more influential than the quality improvement 
itself[27]. Unfortunately, the presence of these explanatory factors is often not 
included in analyses[23]. Therefore, erroneous conclusions may be drawn about the 
possible impact of the intervention on ultimate health if the potential effect of 
antecedents is not sufficiently taken into account when the relationship between QIs 
and patient-relevant outcomes is estimated. If the relationship between applied QIs 
and impact on health status is not adequately validated, the application of particularly 
structural and process QIs may hamper reliable evaluation of ultimate effect on 
patients’ health of potential quality improvements.  
 
 
Figure 3-4. Impact of antecedents on the usefulness of quality indicators for 
evaluation of quality improvements. 
A: antecedents impeding the establishment of causality between an intervention 
and a quality indicator. B: antecedents impeding the establishment of causality 
between a quality indicator and patient-relevant outcome(s).  
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What provides optimal QI(s) for a specific intervention depends on the objective of 
the evaluation. When assessing the reliability of a potential QI for evaluation of a 
quality improvement, the antecedents between the intervention and the QI and 
between the QI and patient-relevant outcomes and their potential to disturb the causal 
inference between the intervention and health status ought to be weighted. As quality 
in healthcare is determined by multiple attributes (Box 3), the impact of quality 
improvements on all attributes is unlikely to be sufficiently embraced by a single 
QI[20,24,62]. Comprehensive evaluation of the impact on all dimensions of the 
quality of healthcare might, therefore, require the application of multiple QIs. 
Likewise, it is possible that a single QI would not adequately capture all impact of a 
quality improvement on a certain aspect of quality, e.g. health status. Again, this 
would necessitate the application of more QIs to reflect all impact.  
To obtain more tangible estimates of the relationship between changes in QIs and 
impact on health, the expected correlation between the QI and outcomes should be 
calculated numerically. With the application of appropriate statistical methods, it 
might be possible to adjust for the presence of antecedents and to quantify the 
uncertainty pertaining to the correlation. This might be usable in analyses of the 
expected cost-effectiveness of interventions. 
 
3.5.3. CHALLENGES	FOR	ECONOMIC	EVALUATION		
OF	QUALITY	IMPROVEMENTS	
Acknowledgment of the importance of the quality of healthcare for economic 
evaluation may best be stirred when considering the differences between the observed 
efficacy in, for example, RCTs and the subsequent, observed effectiveness achieved 
under real-life conditions, where the quality of care may not be as high as observed 
within trial[30,34,62]. It is furthermore recognized that inefficiency in healthcare 
provision and low quality in healthcare coexist, as low quality is either directly 
harmful to patients or because it causes inefficient use of healthcare resources, thereby 
entailing opportunity costs. It could be hypothesized that if the quality of healthcare 
is increased by investment in a quality improvement, the health benefit related to the 
quality improvement will, likewise, increase. [18,24,62] As quality in healthcare thus 
is a determinant of the expected effectiveness and potentially safety of interventions, 
this encourages evaluation of interventions that narrow the gap between real-life 
effectiveness and the technological frontier. Such quality-improving interventions 
may potentially represent cost-effective interventions to increase health gain.  
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The correlation between cost and health benefit related to the level of quality is likely 
to be nonlinear (Figure 3-5)[24]. This creates the foundation for the concept of 
optimality (Box 3), in which the health benefit achieved by investment in a marginal 
quality improvement may not counteract the cost related to the marginal quality 
improvement. Thus, the optimally effective level of quality may not be the maximally 
effective level (Figure 3-5)[62]. At the optimally effective quality level, an 
equilibrium is reached above which further investment in quality will not be 
counteracted by the gain achieved by the investment and where the cost related to ‘a 
unit of quality improvement’ is the lowest. By the introduction of the concept of 
optimality, it is implied that there may be limits to the acceptable costs of quality 
improvement.[13,47] This supports the hypothesis of the present dissertation that 
economic evaluation may be applicable to the area of quality improvement. It also 
highlights the prudence of establishing the value for money of quality improvements 
to substantiate informed decision-making. 
 
 
Figure 3-5. Outline of hypothetical relationship between health benefit achieved by 
increasing quality and the related costs of attaining that quality. A: optimally 
effective quality, B: maximally effective quality. Adapted from Donabedian[62] and 
reproduced with permission from the American Medical Association. 
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Nonetheless, economic evaluation of quality improvements is rarely 
undertaken[16,25]. This may be due to a resistance towards valuation of quality 
improvements because of (misinterpreted) ethical concerns or due to a lack of 
evidence on the impact on health and costs. Often quality improvement is intended to 
increase patient safety by decreasing the risk of treatment-related harm that befalls 
patients or healthcare personnel. To some, it may be of invaluable priority to avoid 
medical errors or medical inadequacy that lead to harm. It might be argued that 
avoiding afflicting further harm on patients cannot be valued. If adopting this attitude 
towards the necessity of avoiding iatrogenic complications, economic evaluation 
would have no bearing on policy decisions on whether to adopt quality improvements 
or not. However, in adopting a normative approach to evaluation, the opportunity 
costs that would be introduced by accepting quality improvements without 
consideration of their expected health benefit and associated costs, might be equally 
harmful to other patients.[18,25,63]  
An additional recurring obstacle to economic evaluation of quality improvement 
remains an apparent lack of acceptable data on resource consumption and the effect 
of interventions[18].  
Considering the diversity of the constituent elements of quality in healthcare, it is 
hardly surprising that approaches to research and evaluation within the ‘informal art 
of quality improvement’ originate from different scientific disciplines. Accordingly, 
the methodologies applied for evaluation of quality improvement derive from, 
amongst others, healthcare science, engineering, and behavioral sciences. The 
different scientific disciplines all have the potential to provide information on the 
value of interventions. They do, however, take different epistemological approaches 
to research and evidence, which may cause disagreements on the validity of evidence 
and the interpretation of results of studies.[24,26,68]  
Whereas the purpose of research in medicine is to improve the clinical evidence on 
the safety and efficacy of interventions, i.e. focused on the final impact on health, 
research on quality improvement in healthcare is to a greater extent focused on 
improvement via the processes of care and the processes themselves[26]. Quality 
improvement is often a dynamic, data-driven process, in which changes are introduced 
continuously to improve outcome and multiple factors are often introduced 
concomitantly. Thus, quality improvements may comprise large, multifactorial 
interventions that cause system changes through complex mechanisms and affect 
more dimensions of quality simultaneously.[19,26,69] It follows that multiple 
antecedents may take effect and hamper the establishment of causal relationships 
between interventions and patient-relevant outcomes. Continuous improvement 
though actions and changes in behavior inherently go against the fundamentals of 
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EBM, in which the causality between a single or a few factors and outcomes is 
determined while other elements are adjusted for. Although EBM – and the RCT in 
particular – may be superior for evaluating medical technology, for which the 
intervention and outcome are clearly defined, it may be less apt for the evaluation of 
multifactorial, complex interventions. Given that the foundation for economic 
evaluation is suffused profoundly by the epistemological basis for EBM, the 
epistemological discrepancy between EBM and research in quality improvement in 
healthcare may be transmitted to the application of economic evaluation to the area of 
quality improvement.[26,69] 
Valid data on costs and effects related to changes in processes of care may thus be 
difficult to obtain. Quality improvement may optimize processes and, in some cases, 
reduce variable costs, but the impact on fixed costs and costs related to a reduced risk 
of patient-relevant outcomes may be difficult to establish with accuracy within the 
study time frames that are often imposed on research in quality improvements.[18,25] 
Furthermore, as previously explained, the effectiveness of quality improvement is 
often measured via QIs. This complicates the evaluation of cost-effectiveness via 
conventional methods, as the QIs may not possess intrinsic value, i.e. not reflect 
change in health, her se. Estimations of cost-effectiveness, in which QIs have been 
applied for effect measure may thus generate unintelligible results.[18,20,65] 
The lack of credible data on health-related effects and costs of quality improvements 
and the methods that are applied to obtain the data constitute a hurdle for economic 
evaluation. However, the increasing use of QIs emphasizes the need for methods to 
establish the cost-effectiveness of such interventions. 
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CHAPTER	4. 	
ATRIAL	FIBRILLATION	
The increasing pressure on healthcare budgets worldwide is partly due to the increased 
prevalence of chronic diseases, such as cardiovascular diseases – including AF[5]. AF 
is the most common cardiac arrhythmia worldwide with an estimated prevalence of 
approximately 3 percent in the general population. The prevalence increases with age 
and more than 6 percent of individuals over 70 years of age suffer from AF. Hence, 
the majority of AF patients are over-65s and the mean age of patients at first diagnosis 
of AF is higher than 70.[70,71] In Denmark, the estimated prevalence of AF is 
120,000 individuals and the current annual incidence is between 15,000 and 20,000 
individuals [29]. The prevalence is expected to rise dramatically in the foreseeable 
future due to the increase in longevity and an increased prevalence of predisposing 
conditions, such as diabetes mellitus, obesity, and prevalent heart failure. 
Consequently, it has been estimated that a quarter of all 40-year-olds in Europe and 
the US will develop AF in their lifetime. [5,70–73] The exact prevalence and 
incidence of AF are unknown as some patients may be undiagnosed due to ‘silent AF,’ 
i.e. asymptomatic AF. In other patients, the disease only manifests itself intermittently 
and the patients may not seek medical attention. Consequently, some patients are not 
diagnosed with AF until they suffer from severe complications related to the 
condition, such as stroke, heart failure, or peripheral arterial embolism, which require 
urgent treatment and may have long-lasting consequences.[28,74]  
In addition to the great personal cost that AF may impose on patients and their 
relatives, the economic burden of AF is substantial[75–78]. Very conservative 
estimates indicate that the direct cost of AF may amount to at least 1 percent of the 
total healthcare expenditure.[75] The complications related to AF, such as stroke, 
constitute the main cost driver[75–77]. In a Danish cost-of-illness analysis from 2016 
Jakobsen et al.[79] found that the three-year societal costs related to first-incident 
ischemic stroke in patients with AF amounted to approximately DKK210,000 (2016 
value) per patient with hospitalizations being the main cost driver. As the prevalence 
of AF is only expected to increase in the future, the costs related to complications are 
expected to also rise[76].  
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4.1. ANTICOAGULATION		
–	THE	CHOICE	BETWEEN	SCYLLA	AND	CHARYBDIS	
In AF, the muscle of the heart atria do not contract efficiently or at a normal pace but 
tremble, which prevents an efficient blood flow through the atria. This increases the 
risk of blood stasis within the atria, which increases the risk of thromboembolism. The 
anomalous contraction of the atria may, furthermore, affect the contraction of the 
ventricles and cause symptoms. The symptoms of AF can be diverse and unpleasant, 
and intrinsically lower patients’ HRQoL, but may be mitigated by appropriate rate- 
and rhythm-controlling medication that stabilizes the erroneous contraction of the 
heart. Despite these therapies, AF still substantially increases all-cause mortality and 
morbidity.[28,80] In a Danish register-based study from 2011, Olesen et al.[81] 
investigated the event rate of thromboembolism (i.e. peripheral artery embolism, 
ischemic stroke, and pulmonary embolism) leading to hospitalization or death of AF 
patients who were not receiving OAC. For uncoagulated AF patients with an 
intermediate to high risk of stroke and systemic embolism (SSE) (cf. section 4.2 for 
elaboration), the rate of thromboembolism ranged from 1.45 to 5.72 per 100 patient-
years [81]. Patients with AF suffer a five-fold increased risk of ischemic stroke, 
compared to patients with sinus rhythm and it has been estimated that 20 to 25 percent 
of all strokes are attributable to AF.[29,80]. As the majority of strokes in AF are 
cardioembolic, they furthermore tend to be more severe and entail greater disability 
and mortality than strokes that are not related to AF[82,83]. The event rate of ischemic 
stroke has been estimated to range from 0.10 to 2.00 per 100 patient-years for 
uncoagulated AF patients with an intermediate to high risk of SSE [84]. Consequently, 
stroke prophylaxis is a critical objective of AF therapy and lifelong OAC is 
recommended for the majority of patients[28,29]. Other nonpharmacological 
approaches to stroke prophylaxis exist, but the use of OAC remains critical in all 
strategies[28].  
OAC reduces the coagulability of the blood and thus prevents stagnant blood from 
coagulating within the fibrillating atria, effectively reducing the risk of 
thromboembolism that may lead to ischemic strokes and other complications. 
Reducing the coagulability of the blood naturally induces an increased risk of 
bleeding. The most severe adverse event of OAC is intracranial hemorrhage (ICH), 
which may entail the same persistent and dire consequences for patients as ischemic 
stroke[85–87]. The rate of ICH has been estimated to range from 0.10 to 0.30 for 
uncoagulated AF patients with an intermediate to high risk of SSE; OAC may increase 
this rate by up to 50 percent.[84] In spite of this, a positive net clinical benefit of OAC 
has been found for the majority of AF patients with an intermediate to high risk of 
SSE, irrespective of their risk of bleeding (cf. section 4.2 for elaboration)[84,88,89].  
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4.1.1. WARFARIN	THERAPY	
In RCTs, the long-used vitamin K antagonist warfarin (Marevan®, Waran®) has been 
shown to reduce the risk of ischemic stroke by approximately two thirds and all-cause 
mortality by one-third for patients with AF compared to placebo and no treatment. It 
thus carries great potential for alleviating the complications that AF may entail[90,91]. 
However, warfarin therapy may be cumbersome for treatment providers and patients 
alike as continual monitoring and dose adjustment of the medication are necessary to 
maintain adequate effectiveness and safety in using the therapy. Warfarin therapy has 
a narrow therapeutic window, meaning that the difference between the effective and 
toxic dose is relatively small, and it therefore entails a nonnegligible risk of 
hemorrhagic adverse events. In addition, warfarin has a substantial number of drug-
drug and drug-food interactions and its effect may be affected further by the genetics 
and concomitant disease of patients. Consequently, there are large intra- and 
interindividual differences in the anticoagulant effect of warfarin therapy, which 
necessitates the continuous routine monitoring and potential dose adjustments to 
maintain the therapeutic effect of the treatment and to avoid serious adverse 
events.[28,29,92] It follows that the effectiveness and safety of warfarin are also 
highly contingent on the achieved quality of therapy.  
 
4.1.2. QUALITY	INDICATORS	IN	WARFARIN	THERAPY	
The quality in warfarin therapy is often described by the use of the QI, time in 
therapeutic range (TTR)[93]. TTR refers to the percentage of time that patients’ 
international normalized ratio (INR) of the blood is within the therapeutic range, that 
is, the target range where the optimal balance between safety and effectiveness is 
achieved[92]. The INR denotes the coagulability of the blood, where an INR of 0.8–
1.2 indicates that the blood coagulates at a normal rate; with a higher INR, the 
coagulability is lower. In warfarin therapy, the optimal intensity of anticoagulation 
for the majority of AF patients obtains a therapeutic range of INR 2 to 3[28,92]. To 
maintain a therapeutic INR level for an individual AF patient, the interval between 
INR measurements is customized to allow adjustment of medication dosages when 
needed. Adjustments are based on the co-medication and -morbidity status and 
coagulation status at previous measurements of the patient. There are no evidence-
based recommendations concerning the optimal interval between measurements. The 
average interval between INR measurements for the majority of patients is 
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approximately three weeks[67,76,94]. Guidelines recommend that the TTR should be 
calculated by linear interpolation between measurements of patients’ INR levels, i.e. 
the Rosendaal principle[29,95]. Thus, the TTR is contingent on both the actual 
coagulation status of patients, i.e. the INR level, and the INR measurement control 
regimen. The TTR is often referred to as an intermediate outcome QI[93], although, 
with reference to the Donabedian framework[23], it could be argued that it is neither 
a true process nor outcome QI, as it depends on both biological functioning (INR) and 
the process of care (the level of coagulation control). 
Nonetheless, the TTR is a well-established QI and demonstrates many of the 
characteristics of the ideal QI; it has the potential to be improved via 
interventions[52,67] and is generally accepted, not based on subjective valuation, 
measurable and replicable, evidence-based, and outcome-validated[20,67,93]. A 
negative relationship between the TTR and the rates of stroke, bleeding, and mortality 
has been established in multiple studies[96–99]. Hence, the longer a patient’s INR is 
within the therapeutic level, i.e. the TTR is higher, the more the risk of 
thromboembolic and hemorrhagic complications is reduced. The importance of 
quality of therapy for the expected safety and effectiveness of warfarin therapy is 
emphasized by evidence suggesting that the TTR of patients should reach 58 percent 
to ensure a net clinical benefit. If a TTR of 58 percent cannot be maintained, the 
potential adverse events related to the therapy will counteract and supersede the 
benefits.[96] In alarming comparison, Mearns et al.[100] found that from 1990 to 
2013 the mean TTR of AF patients in community settings and anticoagulation clinics 
was as low as 55 and 63 percent, respectively. Evidence, furthermore, suggests that 
the quality of therapy has not improved substantially over the last few 
decades[100,101]. Today the quality of warfarin therapy in Denmark is, in general, 
expected to be fairly good and better than in many other countries, with no substantial 
differences in the quality of therapy delivered in general practice and hospital-based 
clinics[102,103]. Nonetheless, in a Danish registry study on data from 1997 to 2011, 
Nissen Bonde et al.[104] found the median TTR for a large Danish AF population to 
be only 64 percent. Although the data are not completely up to date, arguably, the 
effectiveness and safety of warfarin therapy in real-life practice may  still be enhanced 
today if the quality of therapy were improved. 
Due to the multiple factors influencing the effect of warfarin, the ability to achieve a 
high TTR depends on a number of patient-related characteristics, including their sex, 
age, and medical history. Generally, patients with more comorbidities and poorer 
health are less likely to achieve a high quality in warfarin therapy as evaluated by the 
TTR. Consequently, not all patients are likely to be able to obtain a high quality of 
warfarin therapy.[57,104,105] In addition, the quality of warfarin therapy is 
contingent on the organizational setting in which the therapy is monitored and 
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managed. In general, monitoring at anticoagulation clinics is expected to entail a 
higher quality of therapy than community practice, and the quality of therapy 
delivered in relation to RCTs is generally expected to be yet higher[100,101]. 
Likewise, self-monitoring of warfarin therapy has been shown to increase patients’ 
TTR compared to conventionally managed warfarin therapy, though only in highly 
heterogeneous groups[100,106]. This highlights the potential for quality improvement 
in warfarin therapy by, for example, organizational changes. However, the impact of 
clinical and organizational factors on the expected effectiveness and safety of warfarin 
also hampers the transferability of results between settings with dissimilar quality of 
therapy and patient populations. 
The dependency of the TTR on the time between INR measurements introduces some 
uncertainty regarding the TTR as a reliable QI of warfarin therapy. TTR, via linear 
interpolation, does not necessarily reflect the true intensity of anticoagulation between 
the points of measurement. Particularly if the interval between INR measurements is 
large, the INR may fluctuate outside the therapeutic range between coagulation 
controls, placing patients at risk of complications. This would not necessarily be 
detected in the measurements, thereby complicating evaluation of actual quality in the 
therapy via the TTR. The deficiencies of TTR as a reflection of true quality in warfarin 
therapy has spurred the search for other potential quality measures in warfarin therapy, 
including the proportion of INR measurements within the therapeutic range, i.e. 
without interpolation, the variability in INR measurements, and patterns of 
anticoagulation control[107–109]. These measures may improve the prediction of 
adverse events in warfarin therapy compared to the TTR. However, currently, no other 
method for estimating the quality in warfarin therapy has gained the same currency as 
the TTR. TTR is the most often applied QI for warfarin therapy and is used for 
evaluation and setting standards of quality in warfarin therapy in clinical practice 
guidelines[29]. It also represents a reported measure of quality of therapy in research 
settings[39–42].  
 
4.1.3. NON‐VITAMIN	K	ORAL	ANTICOAGULANTS	
The disadvantages of warfarin therapy have spurred the development of NOACs, 
including dabigatran etexilate (Pradaxa®)[39], apixaban (Eliquis®)[40], rivaroxaban 
(Xarelto®)[41], and edoxaban (Lixiana®)[42], which within the last six years have 
become available alternatives to warfarin therapy in Denmark[29]. NOACs have the 
same function as warfarin, but take different mechanisms of actions. Hence, they do 
not exhibit the same number of drug-food and drug-drug interactions as warfarin, 
USING QUALITY INDICATORS IN HEALTH ECONOMIC EVALUATION TO ESTABLISH THE VALUE FOR MONEY OF 
QUALITY IMPROVEMENTS 
46 
making their anticoagulant effect more predictable. This enables the administration of 
fixed-dose medication that consequently reduces the need for frequent routine 
monitoring of coagulation related to warfarin therapy.[34,39–42] In a meta-analysis 
of the phase III trials on the four NOACs versus treatment with dose-adjusted 
warfarin, Ruff et al.[34] found the NOACs to have a preferable balance between 
efficacy and safety compared with warfarin. However, newer observational studies 
from Denmark indicate that, though the NOACs may have a slightly better safety 
profile compared to warfarin, in a routine care setting the effectiveness of the NOACs 
is in general only similar to that of warfarin[30,31].  
Indirect comparisons have been made[37,110,111] that agree that the NOACs are 
more or less comparable, though some find apixaban to be slightly more efficient in 
attaining health[37]. In the RCTs on the NOACs, SSE was used for primary efficacy 
outcome and major bleeding (MB) was used for safety outcome[39–42]. As SSE and 
MB – fortunately – only occur relatively infrequently in AF, the sample size required 
to provide sufficient statistical power to establish noninferiority, let alone superiority, 
is considerable. The patient populations in the RCTs on the NOACs versus warfarin 
were sizeable, ranging from 14,264 to 21,105 included patients [41,42] with median 
follow-ups ranging from 1.8 to 2.8 years[40,42]. The quality in warfarin therapy as 
evaluated by the median TTR of individual patients, furthermore, ranged from 58 
percent to 68 percent[41,42] in the trials. As the relative efficacy and safety of NOACs 
are contingent on the quality of warfarin therapy, transfer of the results from the RCTs 
to settings with dissimilar therapy quality should be performed with caution. It could 
be hypothesized that the relative benefits of the NOACs would be challenged if they 
were compared to truly high-quality warfarin therapy[112]. 
Within the last five years, the use of NOACs has increased in Denmark and 
internationally, whereas the use of warfarin has declined. NOACs may be preferred 
to warfarin therapy, due to the slightly improved efficacy and safety profile, but also 
likely due to the greater convenience that these medication options provides via the 
fixed-dose administration with the reduced need for monitoring. An added benefit of 
this may be increased patient adherence to OAC.[29,32,113] One disadvantage of the 
NOACs remains the medication costs, which for all the NOACs are more than five 
times higher per defined daily dose than the costs of warfarin[35].   
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4.2. GUIDELINES	ON	STROKE	PROPHYLAXIS	THROUGH	THE		
USE	OF	ORAL	ANTICOAGULANT	THERAPY	
Throughout the last decade, clinical practice guidelines for the management of AF 
have developed rapidly[28,29,114,115]. In 2012[114] and 2016[28], the European 
Society of Cardiology (ESC) published updated clinical practice guidelines on 
pharmacological stroke prophylaxis in AF with a more inclusive treatment strategy 
rendering more patients eligible for OAC than previously recommended. The Danish 
clinical practice guidelines on OAC in AF, published by the Danish Council for the 
Use of Expensive Hospital Medicines [Rådet for Anvendelse af Dyr Sygehusmedicin; 
RADS; now the Medicines Council [Medicinrådet]], are in general agreement with 
these guidelines[29,115]. 
According to the guidelines, the decision on whether to initiate OAC should depend 
on patients’ risk of SSE, which can be stratified by the use of the CHA2DS2-VASc 
(congestive heart failure, hypertension, age≥75 [doubled], diabetes, stroke [doubled], 
vascular disease, age 65–74, and sex (female)) scoring system. In the CHA2DS2-
VASc scoring system, each present risk factor yields one point, unless 
doubled[28,81]. The components of the risk stratification scheme represent clinical 
risk factors for SSE, and with higher scores, the risk of SSE increases[81]. Patients 
with a CHA2DS2-VASc score of zero, i.e. zero points, would not benefit from 
OAC[84] and should, according to the guidelines, not receive the treatment, whereas 
patients with a score of 1+ for men and 2+ for women are likely to benefit from the 
therapy and should be treated[28,29]. Considering the relatively high prevalence of 
the risk factors for SSE in an elderly population[116,117], it is hardly surprising that 
the majority of AF patients are considered eligible for OAC[81]. Naturally, clear 
contraindications against OAC should be considered when evaluating the need for 
therapy. A high risk of bleeding is not a contraindication against OAC per se, but 
should make apparent the need to identify the optimal OAC with a low risk of 
bleeding[28–31]. Some risk factors for ischemic stroke and bleeding overlap, 
including a higher age, hypertension, and prior stroke. Relevant risk factors for 
bleeding are summarized in the HAS-BLED (hypertension, abnormal hepatic and/or 
renal function [if both; doubled], stroke, bleeding, labile INR; TTR<60%, elderly; 
age>65, drugs; influencing coagulation and/or alcohol abuse [if both; doubled]) 
scoring system[29,118].  
A change in the Danish clinical practice guidelines from RADS has been introduced 
from the 2013 edition to the 2016 edition. In 2013, all NOACs were assumed to have 
similar effectiveness and safety profiles and were ranked alongside each other 
whereas, in 2016, RADS no longer equated dabigatran etexilate with the other 
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NOACs due to an apparent increased incidence of adverse events and more drug-drug 
interactions compared to the other NOACs[29,115]. This distinction between the 
NOACs is not replicated in the guidelines from the ESC nor in guidelines from the 
Danish Society of Cardiology[28,119]. Thus, in 2016, RADS equated apixaban, 
rivaroxaban, and edoxaban with warfarin, contingent on an expected compliance with 
an a priori explicit, empirical quality standard for warfarin therapy of a TTR of a 
minimum of 70 percent for treated patients. Based on an expectation that the TTR for 
the majority of patients will not reach the quality standard for warfarin therapy, it is, 
rather arbitrarily, recommended that 75 percent of new patients should begin 
treatment with NOACs and 25 percent should begin warfarin therapy. Furthermore, 
patients who do not currently achieve a TTR of 70 percent should be switched to a 
NOAC instead.[29]  
In the clinical practice guidelines from RADS, it is furthermore commented that there 
is a lack of randomized head-to-head studies in which the NOACs are compared with 
high-quality warfarin therapy, i.e. where the mean TTR is over 70 percent[29]. 
However, it does not seem very likely that such studies will be performed in real life, 
considering the resources – and patient population – that would be required to enable 
the execution of such studies.  
 
4.3. ROOM	FOR	IMPROVEMENT	
Clinical practice guidelines summarize the medical knowledge about what is currently 
regarded as the optimal treatment of patients, thereby providing an aid for clinicians 
to make evidence-based decisions regarding optimal healthcare delivery to patients. 
Adherence to the current clinical practice guidelines on stroke prophylaxis in AF, as 
established by a consistency between patients’ risk factors for SSE and subsequent 
observed treatment, has been shown to improve patient outcomes with respect to 
mortality and the incidence of thromboembolism and MB[120,121]. Guidelines 
adherence thus represents an optimization of treatment, when the purpose is to achieve 
the greatest health gain possible.  
With the introduction of NOACs, greater awareness has been raised about the 
appropriate treatment of patients with AF and, consequently, more AF patients in 
Denmark as well as internationally are now treated prophylactically against 
stroke[32,33,122]. In a Danish registry study, Mikkelsen et al.[117] found that in the 
period from 2002 to 2011 only approximately 50 percent of patients newly diagnosed 
with AF in inpatient and outpatient settings were started on OAC within 180 days 
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after the initial diagnosis[117]. By 2011, in a Danish cross-sectional survey Brandes 
et al.[116] found that 66 percent of AF patients who started on antithrombotic therapy 
in general practice were treated with OAC, corresponding to 75 percent of the patients 
being treated in accordance with the 2012 ESC guidelines. Based on this, Brandes et 
al. concluded that the quality of antithrombotic therapy offered to patients with AF in 
general practice in Denmark is reasonably high.[116]  
Despite this, nonadherence to the clinical practice guidelines on stroke prophylaxis in 
AF is still a common difficulty. This leads to patients being un-, under-, or overtreated, 
thereby placing them at unnecessary risk of thromboembolism and bleeding, 
respectively. For instance, acetylsalicylic acid is now considered an obsolete 
thromboprophylactic agent in AF as its benefits do not match those of OAC, but it 
entails the same risk of adverse events[28,91]. Nonetheless, it is still used in clinical 
practice and represents a common undertreatment of AF patients[33,122]. 
Contemporary, international evidence indicate that a substantial proportion – up to 60 
percent – of AF patients receive treatment that is not in agreement with the current 
clinical practice guidelines and that elderly patients in particular remain 
undertreated.[33,116,120–122] Thus, there is still room for improvement. 
The lack of guideline adherence may have multiple causes. In addition to 
considerations of the efficacy and safety of therapies, the clinical practice guidelines 
on stroke prophylaxis in AF also encourage incorporation of patient preferences to 
increase patient satisfaction and persistence with treatment[28,29]. However, the level 
of guideline adherence is often evaluated by a comparison of the clinical indications 
of patients to the subsequent, observed choice therapy for them irrespective of patient 
preferences and satisfaction[33,120,122]. Evidence suggests that up to 30 percent of 
AF patients disprefer OAC despite a clinical indication, which may lead to 
nonadherence to guidelines[123]. If treatment of an individual patient strays from the 
recommendations, it might be due to regard for patient preferences that oppose the 
clinically indicated therapy.[74,123,124] Patient aversion to OAC, furthermore, 
manifests itself in an often-poor persistence with therapy, which is a prevailing 
problem in OAC. Thus, a substantial proportion of AF patients newly started on OAC 
discontinue therapy within the first year of treatment.[32,125–127] Furthermore, 
patients who are not treated with OAC when clinically indicated tend to be older and 
suffer from multiple comorbidities. Nonadherence to clinical guidelines may occur as 
a result of an aversion amongst clinicians to prescribing OAC that might induce 
iatrogenic, hemorrhagic complications in already fragile individuals[33,120,122]. 
This may be particularly true for patients perceived to be at high risk of bleeding, such 
as frail patients, patients at risk of falls, or whose who are clinically disposed for 
bleeding (cf. the HAS-BLED scoring system)[28,74,123].  
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The routine monitoring and difficulties in keeping therapy safe and effective may be 
explanatory factors for potential poor adherence and persistence with warfarin 
therapy[124,127]. These nuisances may be alleviated by the use of NOACs, and 
studies indicate that therapy persistence is improved by using these agents[32,126]. 
Patient-related lack of adherence to, and persistence with, OAC when clinically 
indicated may, however, also be due to ignorance of the risks related to nontreatment, 
which might be ameliorated by improved communication between clinicians and 
patients[74,113].  
Stroke prophylaxis in AF, thus, still holds substantial potentials for improvement. 
Care of this patient population as a whole may be improved by multiple approaches. 
Thus includes increasing the proportion of patients who are initially prescribed 
clinically appropriate therapy and by increasing patient adherence to, and persistence 
with, therapy. Targeting these elements would likely diminish the gap between the 
efficacy frontier of OAC in AF and the observed effectiveness in real life and might 
potentially present cost-effective interventions to the benefit of patients[128,129].
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CHAPTER	5. 	
FIELD	OF	RESEARCH	
This chapter includes summaries of the appended papers and a contextualization of 
the studies into the frame story of the present dissertation. The implications of the 
results of studies II–IV[2–4] are furthermore discussed in a clinical and decision-
oriented context.  
The following section, 5.1, summarizes study I[1], which presents a contribution as 
to how the methods for economic evaluation might be applied to estimate the cost-
effectiveness of quality improvements despite a lack of patient-relevant outcomes. 
Sections 5.2 and 5.3 include contextualization of studies II[2] and III[3] within the 
framework presented in section 5.1. They are used to illustrate examples of 
hypothetical QIs that might be applied to research in interventions intended to 
improve stroke prophylaxis in AF. In section 5.4, study IV[4]  exemplifies the 
establishment of a correlation between an outcome-validated QI, the TTR, and 
patient-relevant outcomes, SSE and MB. It serves as an illustration of the importance 
of finding an appropriate model for the correlation between QIs and patient-relevant 
outcomes and the importance of including relevant antecedents for analysis.  
The overriding purpose of this chapter is to highlight the opportunities for applying 
economic evaluation to quality improvement along with the obstacles to doing so. in 
In Chapter 6, this will lead to a discussion of the overall potentials for doing this and 
a proposal of considerations that should be undertaken prior to the application of 
economic evaluation to quality improvements to optimize the research process. 
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5.1. THE	VALUE	OF	QUALITY	INDICATORS	FOR		
INFORMED	DECISION‐MAKING	
The present section pertains to study I[1] presented in Appendix A.  
5.1.1. SUMMARY	OF	STUDY	I	
Study I advances a framework built on Bayesian decision theory and VOI analysis. It 
concerns the application of DAM to enable evaluation of the NB of quality 
improvements when patient-relevant outcomes are not available and is intended to 
support economic evaluation when QIs are used for indication of effect. The aims of 
the study were to 1) investigate the requirements for QIs to be used in economic 
evaluation and 2) investigate under which circumstances they may be used to enhance 
informed decision-making.[1] 
DAM enables estimation of the expected NB of interventions by utilizing the 
mathematical relationship between the elements in the model. It thus may facilitate 
the inclusion of QIs in the relationship chain between interventions and NB. The use 
of a QI introduces an extra, intermediate link in the relationship between interventions 
and their expected NB, partitioning the correlation between interventions and impact 
on patient-relevant outcomes into two separate parameters: φ1 and φ2 (Figure 5-1). 
The following requirements were identified for QIs to be useful in economic 
evaluation: 
 The intervention should be expected to ultimately affect patient-relevant 
outcomes (i.e. a correlation, φtot, exists between the intervention under 
investigation and patient-relevant outcomes) 
 A quantifiable correlation, φ1, exists between the intervention and the QI  
 A quantifiable correlation, φ2, exists between the QI and patient-relevant 
outcome(s)  
The correlations φ1 and φ2 may be included in DAM as distributions, reflecting the 
uncertainty pertaining to them. If a global correlation φ2 between a QI and patient-
relevant outcome(s) is established, this may subsequently be used to estimate the NB 
of more interventions and studies, in which the QI is used as effect measure and a 
distribution of φ1 is established. To contain the uncertainty related to the correlation 
multiple estimations of the ‘global’ correlation parameter φ2 may be necessary for 
patient subgroups with expectedly different risk profiles for the patient-relevant 
outcomes. As the uncertainty pertaining to the parameters φ1 and φ2 is propagated 
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through the model (Figure 5-1), stronger correlations, i.e. less parameter uncertainty 
of φ1 and φ2, will diminish the impact on final decision uncertainty. When possible, 
relevant antecedents should be adjusted for when φ2 is specified[67]. This may aid in 
containing the uncertainty of the parameter and ensure better reflection of the patient 
population under investigation. If the correlation φ2 is misspecified, it may cause 
incorrect estimations of the expected NB of interventions, leading to erroneous 
conclusions regarding the cost-effectiveness of interventions.[1] 
The use of DAM enables explicit evaluation of parameter uncertainty in the model by 
PSA and ensuing VOI analysis including calculation of the potential cost of 
uncertainty pertaining to the use of the QI, i.e. the expected value of perfect parameter 
information of φ2. Taking a Bayesian decision theoretic approach, it should be 
considered whether the decision uncertainty related to the NB estimated from the use 
 
Figure 5-1. Inclusion of quality indicator(s) as an extra parameter in the 
relationship between an intervention and its final expected NB.  
In study II, the correlation φ2 between a hypothetical quality indicator and the 
occurrence of patient-relevant outcomes is estimated, including the impact on the 
cost of the patient-relevant outcomes. Study III exemplifies how the cost-
effectiveness of an intervention may be estimated based on hypothetical a quality 
indicator and subsequent decision-analytic modeling. Study IV exemplifies the 
establishment of the correlation parameter, φ2, between an acknowledged quality 
indicator and patient-relevant outcomes. NB: Net benefit. Adapted from 
Vestergaard and Ehlers[1]. 
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of the QI indicates that further research might be needed to decrease the risk of making 
the ‘wrong’ decision.  The cost of uncertainty of the different parameters in the model 
should be compared to the expected cost of resolving the uncertainty. This entails 
considerations of what comprises a sufficient data foundation for decision-making – 
whether research to inform on φtot is warranted to resolve the uncertainty pertaining to 
the basis for a decision, otherwise provided by the NB estimated through the use of a 
QI (φ2).[1] 
 
5.1.2. ELABORATION	OF	STUDY	I	
The use of QIs as presented in the framework in study I enables the estimation of the 
NB of quality improvements when evidence on the impact on patient-relevant 
outcomes is not available, a prevalent issue for quality improvements. Studies in 
quality improvement are rarely powered to detect differences in patient-relevant 
outcomes [27,67], yet the need to be able to establish the value for money of quality 
improvements stands unabated and is likely to increase in the future. The focus in 
study I and this dissertation is on the requirements to QI to be applicable in DAM and 
the establishment of the correlation φ2. Less attention is on the establishment of the 
correlation parameter φ1, which depends, amongst other things, on the study design 
used in research in quality improvement. This comprises a topic for further research 
outside the scope of the present thessis. 
The framework builds on the NB framework, which necessitates the existence of a 
threshold for opportunity costs (cf. section 3.3). This, de facto, entails the utilization 
of QALYs as the measure of effectiveness, as a generally accepted threshold exists 
only for this outcome[48]. Consequently, utilization of the framework presented in 
study I requires acceptance of the assumptions that underlie the use of QALYs.  
The chosen QI for a particular model should be expected to embrace all impact on 
health imposed by the intervention. Alternatively, more QIs may be applied, but this 
necessitates their impact on health being mutually exclusive in order to avoid 
overestimation of effect. Once a relevant QI is identified, correct specification of the 
φ2 is pivotal to avoid misleading estimations of NB. VOI analysis only illustrates the 
uncertainty of the parameters and not their correctness. Consequently, VOI analysis 
cannot be used to uncover an erroneous φ2 specification, emphasizing the need for 
careful consideration when it is specified. If the ‘distance’ between the applied QI and 
patient-relevant outcome is substantial, more antecedents may influence the 
correlation φ2 and inflate the uncertainty pertaining to it, causing mistrust in the results 
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of analyses. Antecedents may induce effect modification and confounding, which 
stresses the need for adjustment. If not all relevant influences are recognized and 
included, the model suffers the risk of unobserved confounding. For this reason, it is 
important to identify potential antecedents and, if possible, adjust for their influence. 
To achieve this, a good overview of potential causal relationships and correlations 
between elements in the research setting under study is required. When possible, the 
accuracy of the correlation between the QI and patient-related outcomes, φ2, should 
be validated against real-life data prior to its application. 
The framework presented in study I reflects the same approach to decision-making 
under uncertainty as observed for economic evaluation incorporating clinical, 
intermediate endpoints. A viable clinical, intermediate endpoint should constitute a 
substitute for final, patient-relevant outcomes and be predictive of these For the use 
of clinical, intermediate endpoints in economic evaluation it is, likewise, suggested 
that a quantifiable and stable relationship between the endpoints and patient-relevant 
outcomes should exist and all uncertainty related to assumptions and parameter inputs 
should be highlighted. Likewise, VOI analyses are recommended.[13,53] One 
principal difference between the framework presented here and the existing 
recommendations on use of clinical, intermediate endpoints for DAM consists in the 
interpretation of what may constitute the intermediate link in the relationship between 
interventions and NB. Research in clinical, intermediate endpoints takes its origin in 
EBM and clinical, intermediate endpoints are often biomarkers or indicators of 
physiological changes known to eventually affect health.[53] The recommendations 
thus embraces only outcome QIs. In contrast, the present framework accepts the 
incorporation of any links not necessarily related to physiological functioning, i.e. also 
structural process QIs, in the relationship between interventions and NB under the 
expectation that the uncertainty it entails is sufficiently illustrated. It is likely that 
some of the experiences of the incorporation of clinical, intermediate outcomes in 
DAM may be transferred to economic evaluation of quality improvements where QIs 
are used for outcome.	 	
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5.2. LINKING	QUALITY	INDICATORS		
TO	PATIENT‐RELEVANT	OUTCOMES		
The present section pertains to study II[2] presented in Appendix B. 
5.2.1. SUMMARY	OF	STUDY	II	
Clinical practice guidelines recommend that AF patients resume OAC following an 
ICH unless contraindicated[28,114]. The recommendation is based on the expectation 
that this treatment course, on average, provides a greater net clinical benefit than 
discontinuation, as long as relevant risk factors for bleeding and the cause of the initial 
ICH have been sufficiently treated[28]. The primary aim of study II was to estimate 
the three-year hospitalization cost (2015 value) related to thromboembolism and MB 
for two patient groups with AF who survived the first 90 days following an ICH: 1) 
patients who resumed warfarin therapy within the 90 days following the ICH and 2) 
patients who did not resume therapy within this period.[2] 
The study was performed as a registry study based on the nationwide Danish 
registries, providing information on patients’ baseline characteristics, diagnoses, 
hospitalizations, and medications. The effect of warfarin therapy resumption on three-
year hospitalization costs and survival was estimated by the use of regression analysis 
with adjustment for between-group differences in baseline characteristics. The 
marginal effect of therapy resumption on mean hospitalization costs was estimated 
through the use of a two-part model, comprising a logistic regression model and a 
generalized linear model. The impact on survival was evaluated through the use of the 
Cox proportional hazard ratio. All analyses were adjusted for the individual 
components of the CHA2DS2-VASc and a modified HAS-BLED score at day 90 post-
ICH. The study design is illustrated in Figure 5-2.[2] 
When adjusting for differences in baseline characteristics, the odds ratio for 
hospitalization of patients resuming warfarin therapy was 0.92 [95%CI: 0.65;1.31] 
compared to patients who did not resume therapy. The marginal effect of therapy 
resumption on hospitalization costs for hospitalized patients was DKK-12,101 
[95%CI: -22,289;-1913]. When combining the models, the marginal effect of therapy 
resumption on hospitalization costs was DKK-3101 [95%CI: -6211;15]. The baseline-
adjusted hazard ratio for mortality was 0.79 [95%CI: 0.61;1.01] for patients resuming 
therapy versus patients not resuming therapy.[2] 
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5.2.2. CONTEXTUALIZATION	OF	STUDY	II	
Trial-based evidence on the effectiveness and safety of OAC following ICH in AF is 
scarce as prevalent ICH is a common reason for excluding patients from trials, 
including the major trials on the NOACs[39–42]. However, the results of study II are 
in agreement with other observational studies indicating that the resumption of 
warfarin therapy following an ICH in AF may represent the optimal treatment course 
for the majority of AF patients[130,131]. Thus, evidence suggests that patients 
resuming therapy experience a higher survival and fewer hospitalization-requiring 
complications. Study II provides both a clinical and financial incentive to motivate 
guideline adherence, i.e. OAC resumption after ICH. The study does, however, most 
likely suffers from unobserved confounding, including confounding by indication. 
The Danish registries do not hold information on the subtype of the ICH, which may 
decide for whether OAC resumption is expected to be beneficial or not[132–134]. 
This information may have been a deciding factor in whether to resume therapy or 
not. Likewise, patients’ health status and preferences towards treatment after the ICH 
is unknown, which may have influenced the decision.[2] 
As resumption of OAC after bleeding is generally recommended in guidelines[28], 
OAC resumption could, hypothetically, constitute a QI that might be used to evaluate 
the quality of care of patients with AF. In that case, it would be recognized as a process 
QI referring to the initial decision on whether to resume therapy or not. It would be a 
binary indicator of ‘resumption of therapy following ICH, yes/no’ and accordingly, 
not indicate the level of quality of subsequent continuous therapy of patients. Study II 
confirm that there is a (nonsignificant) correlation between resumption of OAC and 
patient-relevant outcomes (φ2) and the costs related to them, thereby validating it as a 
potential, though uncertain, QI. It furthermore illustrates how the correlation 
parameter, φ2, between the QI and the outcomes may be estimated by using regression 
analysis with adjustment for a priori chosen covariates – or antecedents – known to 
affect the occurrence of patient-relevant outcomes and potentially also the initial 
decision to resume therapy. The occurrence of patient-relevant outcomes may, 
however, also be affected by a multiplicity of factors after the initial resumption 
decision, e.g. patient nonadherence to therapy. These cannot and should not be 
adjusted for in analysis. These factors may be contributory to the inability to establish 
a statistically significant relationship between the process QI and the occurrence of 
thromboembolism and MB. 
If therapy resumption after ICH were to be used as a QI, it might not make sense to 
use it as an indicator of quality of therapy for the individual patient, as a number of 
patient-specific elements may influence the decision as to whether to resume therapy. 
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Instead, it might be used for patient cohorts as the ‘proportion of AF patients resuming 
therapy following ICH.’ It may, however, prove difficult to set quality standards, e.g. 
a minimum proportion of patients that should resume therapy, as the decision to 
resume therapy or not should reflect the clinical situation at hand[131].  
Study II exemplifies the difficulties in establishing statistical significance that may 
arise when studying relatively rare conditions and the occurrence of relatively rare 
complications in these. Even with one of the largest database sources available it was 
not possible to generate statistically significant results when applying unaggregated 
outcome measures[2]. Small samples and very infrequent occurrence of patient-
relevant outcomes are, likewise, a prevalent issue in research on quality improvement. 
Nonetheless, decisions must be made, which supports a Bayesian approach to 
decision-making with less focus on statistical inference and a greater focus on 
highlighting the potential cost of uncertainty related to decision-making under 
uncertainty.  
Although both the hospitalization costs and mortality were lower for the group 
resuming OAC, the health economic potential of the intervention, resumption of 
therapy, remains obscure. As stated in the discussion in study II[2], the savings in 
hospitalization costs imposed by therapy resumption would not counteract the costs 
related to the delivery of warfarin therapy and, arguably, neither the applied 
perspective nor the time horizon enables the inclusion of all relevant costs. In addition, 
the use of the one-dimensional effect measure, survival, likely also underestimate the 
impact on health under the two treatment courses, given that thromboembolism and 
MB negatively influence HRQoL. Although a tendency towards dominance of therapy 
resumption was observed in study II, i.e. lower costs and improved survival, DAM 
would be warranted to enable the acquisition of interpretable cost-effectiveness results 
in a broader perspective. It is expected that the benefits of therapy resumption would 
be augmented in such an analysis.  
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5.3. MODELING	VALUE	FOR	MONEY	BASED	ON		
A	QUALITY	INDICATOR	
The present section pertains to study III[3] presented in Appendix C. During her 
master thesis, the author of the present dissertation developed a preliminary model for 
the decision-analytic model applied in study III. As a part of the Ph.D., the model has 
ensuingly been refined for publication in study III[3]. 
5.3.1. SUMMARY	OF	STUDY	III		
In the clinical practice guidelines on pharmacological stroke prophylaxis in AF 
published by the ESC in 2012[114] a larger proportion of AF patients were considered 
eligible for OAC than previously estimated. Study III evaluated the cost-effectiveness 
of optimizing therapy of the Danish AF patient population by complete adherence to 
the 2012 ESC clinical practice guidelines compared to the treatment strategy observed 
prior to 2012.[3] 
A CUA was performed to compare the guideline-adherent treatment strategy to the 
strategy observed prior to 2012. Guideline-adherent treatment included the use of a 
NOAC (dabigatran etexilate), warfarin, and no treatment; the comparator included 
warfarin, acetylsalicylic acid, and no treatment. A Markov model was designed to 
reflect the expected courses of treatment under the two strategies, including potential 
complications arising from the different treatments. A patient cohort was modeled 
with a risk profile reflecting that of the Danish AF patient population as evaluated by 
patients’ CHA2DS2-VASc scores, established from register-documented conditions. 
The CHA2DS2-VASc scores were used to allocate patients into different therapies 
under the guideline-adherent treatment strategy. The model was populated with 
information on input parameters from the literature. The data were chosen based on 
the criterion that they should expectedly best reflect the Danish context and local cost 
data (2014 value). The applied perspective was that of the Danish healthcare sector, 
including patient-paid cost of medication.  The model ran over a 10-year time horizon 
with a three-month cycle length.[3] 
Based on the decision-analytic model, the ICER for the guideline-adherent treatment 
strategy versus the strategy observed prior to 2012 was approximately DKK 26,500 
per QALY, which would be well below a potential threshold for opportunity costs of 
DKK 185,000 per QALY (≈£20,000/QALY). Both deterministic sensitivity analyses 
and PSA indicated that the result was largely robust to reasonable changes in 
assumptions and input parameters.[3] 
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5.3.2. CONTEXTUALIZATION	OF	STUDY	III	
Study III presents an alternative approach to improving the health of a patient 
population by comparing treatment strategies including the utilization of multiple 
medication types instead of comparing two or more individual treatments as is more 
common in economic evaluation. The cost-effectiveness of the individual medications 
has been established previously[36–38], for which reason it was not the main concern 
of the study. The purpose of clinical practice guidelines is to indicate what is clinically 
optimal. Hence, they do not explicitly include considerations of cost-effectiveness of 
neither the individual medications nor the treatment course they recommend. 
Therefore, the focus was on identifying the cost-effectiveness of adhering to the 
guidelines, as this would represent an improvement of the quality of therapy. It should 
be noted that though the pre-2012 treatment strategy represents suboptimal treatment 
by current standards, it might reflect acceptable treatment at the time when it was 
provided, although this is unlikely[23]. However, if the pre-2012 strategy also reflects 
current treatment practice, this would represent suboptimality, which could be 
ameliorated by enhanced guideline adherence. 
Whereas economic evaluation is often applied to identify the incremental cost-
effectiveness of utilizing one treatment instead of another, study III also incorporates 
the impact of treating a larger proportion of the patient population in accordance with 
guidelines. In the pre-2012 strategy, only 37 percent were treated with warfarin, 19 
percent were treated with acetylsalicylic acid, and 44 percent were untreated, which, 
by current standards, reflects a substantial undertreatment. In the guideline-adherent 
treatment strategy, only 9 percent would be appropriately untreated, based on their 
CHA2DS2-VASc score. This illustrates that optimizing prophylaxis for this patient 
population by treating a larger proportion of the AF patient population with OAC is 
highly cost-effective (DKK26,500/QALY); irrespective of the fact that medication 
costs would increase. Sensitivity analyses, furthermore, indicated that the cost-
effectiveness was not contingent on what subtype of OAC, warfarin or NOAC, was 
utilized. Study III thus indicates that it may be clinically and health economically 
beneficial to improve the quality of therapy for the patient population as a whole by 
focusing not only on which intervention to use, i.e. warfarin or NOACs, but also for 
whom. That is, identifying all eligible patients and treating them according to current 
medical knowledge.  
To enable the construction of the decision-analytic model, a number of simplifications 
of reality were necessary, which are open to discussion. The Markov model reflecting 
the guideline-adherent treatment strategy is built on the assumption that patients 
remain treated throughout the investigated time horizon, which in real life may not be 
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realistic. As the patient population ages, conditions may furthermore arise, which are 
not included in the model, that preclude the continuation of OAC. This is not included 
in the model. In addition, the distribution into different therapies under the guideline-
adherent treatment strategy is solely based on the risk profile, the CHA2DS2-VASc 
distribution, of the Danish patient population and does not take into account potential 
contraindications for OAC, nor patient preferences.  
Hypothetically, treatment of patients in accordance with clinical practice guidelines 
could be used as a process QI for treatment in AF, reflecting continuous adherence to 
guidelines over time. The correlation φ2 between the QI and patient-relevant outcomes 
is established implicitly via the use of medications, for which the relationship with the 
outcomes has been established previously. Thus, study III illustrates how the cost-
effectiveness may be established based on a QI, here the binary QI, ‘treated according 
to guidelines, yes/no.’ Given the model structure presented in study III[3], this 
potential QI cannot be used for the evaluation of quality of therapy of the individual 
patient, but may reflect quality of therapy for cohorts. As such, it might be employed 
as the ‘proportion of patients treated according to guidelines over time.’ In this, the 
correlation, φ2, between the QI, via utilization of relevant medications, and patient-
relevant outcomes is used to estimate the potential cost-effectiveness of perfect 
guideline adherence by conditional linking of the consequences for costs and effects 
that perfect guideline adherence incurs (Figure 5-1). The decision-analytic model in 
study III does not explicitly incorporate the potential influence of antecedents. 
However, the evidence used to populate the model was intended to reflect the Danish 
patient population, for which reason the correlation between the two strategies, 
through the use of the various medications, and patient-relevant outcomes is expected 
to represent what would be observed in real life. 
In practice, 100 percent guideline adherence for cohorts is unobtainable, but the model 
could be expanded to evaluate the cost-effectiveness of interventions seeking to 
improve guideline adherence. To include an intervention that influences the QI, i.e. 
‘proportion of patients treated according to guidelines over time’, in the model, the 
additional uncertainty parameter φ1 should be included to the left in the model 
structure presented in study III (Figure 5-3). This would enable indication of expected 
proportions of patients treated according to the 2012 ESC clinical practice guidelines 
and the pre-2012 treatment strategy, respectively, with and without an intervention to 
improve guideline adherence. This model structure also enables inclusion of the 
expected costs related to the intervention under investigation (Figure 5-3). The same 
structure could be set up to include an intervention and φ1 for the hypothetical QI 
presented in study II. 
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Figure 5-3. Illustration of the introduction of a hypothetical intervention to improve 
guideline adherence. In all probability, 100 percent guideline adherence cannot be 
achieved, but it may be increased by an intervention (p in the upper branch of the 
decision tree). The costs related to the intervention should be included in the model. 
*Confer study III[3] for explication of the Markov models.  
	
5.4. EMPIRICAL	INVESTIGATION	OF	A	QUALITY	INDICATOR		
The present section pertains to study IV[4] presented in Appendix D. 
5.4.1. 	SUMMARY	OF	STUDY	IV	
As previously explicated, TTR is a generally accepted QI in warfarin therapy and a 
negative linear relationship between TTR and complication rates has been 
demonstrated[67,96–99]. Increasing TTR therefore represents a quality improvement 
by decreasing the risk of serious adverse events. The occurrence of thromboembolism 
and bleeding is, however, also contingent on patients’ risk profile, often summarized 
by the CHA2DS2-VASc and HAS-BLED scores. Previously, patients’ risk profile has 
not been taken into account when the correlation between TTR and complications has 
been estimated. Evidence, furthermore, suggests that the relationship between TTR 
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and complications may not be completely linear, as increasing the TTR at lower levels 
of TTR reduces the risk of complications, whereas this effect is not observed for 
higher TTR levels, i.e. at TTRs above 70 percent[135,136]. Combined, this calls into 
question the accuracy of the previously established relationship. The aim of study IV 
was to evaluate the correlation between the mean TTR of AF patient cohorts and the 
occurrence of patient-relevant outcomes with adjustment for patient cohort 
characteristics known to affect patients’ risk of events.[4] 
The data used for study IV were retrieved through a focused, structured literature 
review. Thirty-five papers with information on 31 patient cohorts, including 
information on more than 100,000 AF patients, were extracted based on pre-specified 
criteria. A linear random-effects meta-regression with and without adjustment for a 
priori chosen covariates was performed to illustrate the association between mean 
TTR in the study cohorts and the occurrence of SSE and MB. Supplementary analyses 
were performed for hemorrhagic and ischemic stroke, respectively. Analyses of the 
hemorrhagic outcomes were adjusted for the mean age and proportion of the 
population with previous stroke or transient ischemic attack. For analyses of the 
ischemic outcomes, the proportion of the population that was female was, 
furthermore, included. A modified double arcsine transformation was applied to the 
outcome data for normalization, to avoid overdispersion, and to stabilize variances.[4] 
As expected and previously shown, in the univariable meta-regression with mean TTR 
as single predictor, higher mean TTR was statistically significantly and negatively 
related to the double arcsine transformed rates of both MB and SSE. In adjusted 
analyses, mean TTR was still statistically significantly related to the rate of MB, but 
not with the rate of SSE. Study IV indicates that increasing the quality in warfarin 
therapy by increasing the mean TTR of a patient cohort is clinically beneficial. 
However, when adjusting for clinically relevant characteristics of the cohorts, 
increasing quality in therapy mainly improves the safety of therapy by decreasing the 
MB rate, whereas the rate of SSE, though still inversely associated with mean TTR, 
is only negligibly decreased.[4] 
  
5.4.2. CONTEXTUALIZATION	OF	STUDY	IV	
Other potential QIs for warfarin therapy exist that could have formed the basis for 
evaluation in study IV, some of which may represent better QIs than TTR (cf. section 
4.1.2). However, as TTR is generally accepted as a QI in warfarin therapy, greater 
knowledge about it and its association with complications may potentially be used to 
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aid decision-making. When taking a pragmatic, application-oriented approach, the 
widespread and acknowledged use of TTR merits its application in the present study. 
Furthermore, TTR is often reported in studies, which provided a larger evidence base 
for the study than would have been possible for other potential QIs. To the best of the 
author’s knowledge, no real-life studies have been performed with the specific 
purpose of establishing the relationship between mean TTR and patient-relevant 
outcomes. Consequently, the health economic impact of increasing quality in warfarin 
therapy as measured via mean TTR is currently unknown. For this reason, in study IV 
evidence was compiled from the literature in an attempt to establish the correlation. 
The ulterior motive for the conducting of the study was to make the estimated 
correlation(s) accessible for further use in the framework presented in study I to 
subsequently enable economic evaluation of interventions intended to increase TTR.  
A pragmatic approach was taken to the study design, balancing the desire for the right 
evidence with the need for sufficient evidence to support the analyses. The primary 
outcomes investigated in the study, MB and SSE, are largely suboptimal in a health 
economic context as the related costs and effects of the aggregated outcomes may be 
highly dissimilar. This may be especially true for the outcome MB, which includes 
ICH that on average entails more severe consequences for patients’ expected disability 
level, costs, and very survival compared to extracranial hemorrhage. Preferably, from 
a health economist perspective, the study should have included less aggregate 
outcomes, but the evidence base on separate outcomes was too small to substantiate 
valid analysis. Furthermore, the current adjustments in the multivariable meta-
regressions were performed based on the availability of the data. The majority of the 
included studies did not report on all parameters of interest and in order to keep a 
sufficient evidence base for analysis, adjustment was only performed for basic 
characteristics of the patient populations. [4] Ideally, the analyses might have included 
adjustment for more factors known to influence the occurrence of outcomes. As it is, 
study IV likely suffers from some effect modification and unobserved confounding. 
Multiple assumptions were made for the execution of study IV, which should induce 
caution when making inferences based on the study results. The studies used in the 
meta-regression were heterogeneous and the reporting applied in the studies was, 
likewise, dissimilar. Nonetheless, data from the studies were combined to enable 
analysis of the reported mean value. As such, ecological bias may exist.[4] For future 
research, the correlation between TTR and complications might be performed on the 
individual level with adjustment for a more complete set of relevant variables[67]. 
This might validate the rates predicted from study IV, which is currently lacking. 
The hypothetical QIs investigated in studies II and III were binary indicators reflecting 
‘resumption of therapy following ICH, yes/no’ and ‘treated according to guidelines, 
yes/no,’ resulting in quality indication by the ‘proportion of patients resuming 
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therapy’ and ‘proportion of patients treated according to guidelines,’ respectively. In 
contrast, the QI, TTR, represents the level of quality in continuous therapy and is used 
to evaluate the quality of ongoing therapy. The meta-regressions indicating the rates 
of SSE and MB as functions of TTR constitute two correlation parameters, φ2, which 
may be applied simultaneously in the same decision-analytic model to more 
sufficiently include the impact on health of increasing mean TTR. As the data in study 
IV were aggregated as the mean values of cohorts and the covariates were included as 
proportions in the meta-regressions, the results of study IV are likewise only 
applicable on a cohort level, i.e. reflecting the correlation between mean TTR and 
outcomes on a population level and not for the individual.  
In study IV, the double arcsine transformation was applied to the rates of MB and 
SSE, producing a slightly nonlinear relationship between the mean TTR and the 
outcomes in the original scale (Figure 5-4). This estimation of the correlation to some 
degree facilitates the real-life observations that TTR is not correlated with 
complication rates at high values[135,136]. Consequently, in the present model, the 
clinical benefit of increasing TTR at high values would not be as high as increasing it 
at low values. It could be hypothesized that the costs of increasing mean TTR when 
quality of therapy is already high are similar to, or higher than, the costs related to 
quality improvements at lower levels of quality. This would be in agreement with the 
expectation presented by Donabedian that the marginal benefit (here, decreasing rates 
of MB and SSE) of improving quality may potentially not counteract the costs related 
to attainment of the quality(Figure 3-5)[24,62]. Evidence that the rate of 
complications does not correlate with the level of TTR above 70 percent[135] 
suggests that the optimally effective quality in warfarin therapy may exist at a mean 
TTR of 70 percent. Above this level of quality, the marginal health gains achieved by 
quality improvement may be bought too dearly if the cost of quality improvement 
increases at higher levels of quality. Thus, it is possible that above a mean TTR of 70 
percent further investment in quality improvement in warfarin therapy may not be 
cost-effective. This remains to be elucidated.  
The correlation between mean TTR and patient-relevant outcomes found in study IV 
might be used to model the expected cost-effectiveness of warfarin therapy at different 
levels of quality, i.e. different mean TTRs, through the use of the framework presented 
in study I. Increasing quality in warfarin therapy may be achieved through different 
initiatives, including the use of self-monitoring in eligible patient groups[100,106]. 
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Currently the cost-effectiveness of self-monitored warfarin therapy in AF is obscure, 
as no studies provide sufficient evidence on the occurrence of patient-relevant 
outcomes in self-managed therapy for AF patients alone. Evidence on TTR does exist, 
however, which may be used to model the expected NB, if the correlation presented 
in study IV is accepted. The correlation φ2 may be used in DAM to compare, for 
instance, self-managed warfarin therapy, conventionally managed warfarin therapy, 
and the use of NOACs. This may indicate whether quality improvement in warfarin 
therapy provides a viable alternative to the use of new medication for eligible 
patients[112,135]. An outline of a Markov model-based decision analysis with the 
utilization of the correlation found in study IV is exemplified in Figure 5-5. In the 
model, the impact of differing quality of therapy as evaluated by the mean TTR would 
be reflected in the transition probabilities for SSE and MB in self-managed and 
conventional warfarin therapy. Modeling of the expected cost-effectiveness of 
warfarin therapy at different levels of quality has been done before[128,137]. 
However, previously only univariable, linear regression analyses have been utilized 
to estimate the impact of increasing TTR on complication rates, thereby disregarding 
the potential impact of other factors. Furthermore, the potential cost of uncertainty 
related to the use of the expected correlation has not been investigated sufficiently, 
which would be highly relevant for investigating the validity of the primary results 
and impact on the decision uncertainty.  
Study IV illustrates how the mathematical correlation between an outcome-validated 
QI for the level of quality and patient-relevant outcomes may be estimated with 
adjustment for relevant antecedents. The study also highlight some of the obstacles to 
doing so. Due to the rarity of events, a common issue in research in quality 
improvement[27], multiple studies may need to be aggregated to enable estimation of 
the correlation φ2. Preferably, however, data should be retrieved on the individual 
level allowing for more accurate data and informative analyses. Study IV illustrates 
the importance of adjusting for factors that affect the occurrence of the patient-
relevant outcomes; not adjusting for relevant variables may bias the association and 
the correlation may be misspecified[67,105].  
Utilization of misspecified correlations could lead to erroneous conclusions on the 
cost-effectiveness of interventions that increase the quality of therapy. If, for instance, 
a linear relationship between mean TTR and complication rates were applied or if 
appropriate adjustments were not performed, the benefits of increasing mean TTR 
might be erroneously inflated, potentially leading to unreasonably optimistic results 
on the impact of improving quality in warfarin therapy.  
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CHAPTER	6. 	
DISCUSSION	AND		
CONCLUDING	REMARKS	
6.1. IMPROVING	ORAL	ANTICOAGULANT	THERAPY		
IN	ATRIAL	FIBRILLATION	
Evidence on the comparative cost-effectiveness of OAC agents used in AF is vast[36–
38]. For this reason, rather than providing confirmations of the results of previous 
economic evaluations of the different medication types, the clinical aim of the present 
dissertation was to illustrate the health economic potentials of other approaches to 
improving OAC in the AF population as a whole. Consequently, decision-making on 
therapy of the AF patient population has been approached from a general, policy 
decision-oriented level. The approach to decision-making presented here may be used 
as an aid in organizational considerations and in policy decision processes e.g. on 
which initiatives to reimburse on a patient population level, based on their mean, 
expected cost-effectiveness. Economic evaluation of alternative quality improvement 
may help identify focus areas that could be prioritized in future policy decisions. It is 
not intended to replace clinical judgement and decision-making in the treatment of 
individual patients.  
As exemplified in study II and III[2,3], more focus areas for quality improvement in 
OAC exist, where improvement of the treatment of the AF patient population may be 
cost-effective. There appear to be a potential in ensuring that more patients are treated 
in accordance with clinical practice guidelines on stroke prophylaxis in AF [3,28,29]. 
Greater guideline adherence in the treatment of the patient population as a whole 
might increase equality in care provision with less unsubstantiated nontreatment, 
while representing a cost-effective treatment strategy[3]. Furthermore, 
discontinuation of OAC following an ICH is more common than resumption of 
therapy, although, on average, resumption of therapy appear to improve morbidity, 
mortality, and entail lower hospitalization costs[2,130,138]. Raising awareness 
amongst clinicians and patients alike of the net health benefit associated with OAC in 
AF might increase the proportion of patients resuming OAC following ICH and 
potentially represent a cost-effective quality improvement[2]. Lastly, therapy may 
also be improved by increasing the level of quality in the therapy delivered[4]. 
Although NOACs are increasingly used for OAC in AF, a large proportion of patients 
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are still in warfarin therapy[30,31]. Different approaches may be employed to improve 
the quality in warfarin therapy of patient cohorts, e.g. by use of specialized OAC 
clinics or self-managed warfarin therapy[100]. The cost-effectiveness of using 
specialized OAC clinics and self-managed warfarin therapy compared to conventional 
warfarin therapy managed in general practice is currently unknown. The cost-
effectiveness is contingent on the effectiveness and safety observed under the different 
levels of quality of therapy delivered in the different settings. The quality may be 
evaluated by their mean TTR. However, the occurrence of patient-relevant outcomes 
is not contingent on the quality of therapy of patient cohorts alone, but is also affected 
by other factors[4,81,118]. Therefore, relevant characteristics of the patient 
populations for whom the quality of therapy might be improved should be taken into 
account when evaluating the cost-effectiveness of improving quality of therapy. The 
same may apply to the characteristics of the settings in which the therapy is delivered. 
If this is neglected, the health economic impact of improving quality of therapy may 
be misestimated[1,4].  
 
6.2. EVALUATING	THE	VALUE	FOR	MONEY	OF		
QUALITY	IMPROVEMENTS	–	FUNDAMENTAL	OBSTACLES	
The social objective of economic evaluation is in general agreement with the main 
purpose of quality improvement in healthcare, i.e. to improve health [13,23]. This 
substantiates the potentials of applying health economic evaluation to establish the 
value for money of quality improvements. There are, however, also fundamental 
differences in the scope of the two scientific disciplines, in what composes viable 
effect measures, the understanding of evidence, and the execution of research, which 
should be acknowledged.  
As economic evaluation is founded in normative health economics, its methodology 
is suffused by the core principles of welfare economics. Thus, the extra-welfarist 
economic evaluation employs the focus of identifying the efficient allocation of 
resources. In addition, it is distinctly result-oriented, in general accepting only 
outcomes for analysis that reflect impact on health.[13,45,47] In contrast, quality 
improvement is often process-oriented, accepting intermediate goals for outcomes, for 
instance, reflecting changes in processes that might not affect health, per se, and from 
which ultimate impact on health may occur at an immeasurably slow rate[26,27]. 
Furthermore, quality in healthcare is composed of multiple constituent elements and 
consequently quality improvement in healthcare may target multiple foci[62,64]. 
CHAPTER 6.  
DISCUSSION AND  
CONCLUDING REMARKS 
73 
Thus, quality improvement may target other aspects of quality in healthcare than the 
efficient allocation of resources, e.g. equal access to healthcare or greater 
incorporation of patient preferences. Impact on these elements of quality in healthcare 
might not result in measurable impact on health, but are undoubtedly still of 
value.[21,43,62] Thus, there may be an inconsistency between the ‘value’ that the 
improvement brings and the understanding of ‘value’ employed in conventional 
economic evaluation, restricted to include impact on health. Arguably, the application 
of economic evaluation might then be considered moot when the aim of the 
intervention is not to improve health per se, as the measure of effect in the evaluation 
would not reflect the purpose of the intervention. This discrepancy should be 
acknowledged if economic evaluation is employed to identify the value for money of 
quality improvements targeting elements of quality in healthcare that do not change 
either resource consumption or health accumulation. As conventional economic 
evaluation is only intended to embrace a part of the potential impact that quality 
improvement may entail, it could therefore be discussed whether economic 
evaluation, by its current methods, provides appropriate evaluation for such 
interventions.  
The main objective of the healthcare system is to improve the health of the 
population[43,47]. Efficient use of the resources in the healthcare system supports this 
objective[13]. If the cost-effectiveness of quality improvements cannot be confirmed, 
their introduction in the healthcare system should therefore be thought critically 
through. It might be that the reason why cost-effectiveness cannot be established is 
that the ‘value’ that the quality improvements bring is difficult to quantify and include 
in conventional economic evaluation. If that is the case, it should be considered 
whether the level of that ‘value’ is enough to justify the introduction of the quality 
improvements, although the immediate value, restricted to the extra-welfarist 
understanding of the term, for money they bring would not be sufficient to support 
their utilization under an extra-welfaristic approach to decision-making. Satisfaction 
with care, equity concerns, and other constituents of quality in healthcare are evidently 
of increasing interest and therefore of value, but these dimensions of healthcare 
delivery are currently not explicitly included in economic evaluation[20–22].  
It could be argued that some elements of quality in healthcare, which are not explicitly 
included in conventional economic evaluation, such as patient preferences towards 
care, may be included implicitly through impact on, for instance, patients’ compliance 
and adherence to therapy. This might derive impact on the occurrence of patient-
relevant outcomes that consequently would be includible in economic evaluation. It 
follows, that in some instances it might still be possible and reasonable to perform 
economic evaluation of interventions targeting these elements of quality in healthcare, 
as impact on health may eventually be observed. Explication of the purpose of 
USING QUALITY INDICATORS IN HEALTH ECONOMIC EVALUATION TO ESTABLISH THE VALUE FOR MONEY OF 
QUALITY IMPROVEMENTS 
74 
individual quality improvements may substantiate their importance and defer 
subjugations of evaluation of their health economic potential by conventional 
methods, if the interventions are not intended to improve elements influencing 
efficiency in resource allocation. Likewise, clarifications of the ultimate purpose of 
quality improvements may aid the identification of interventions for which economic 
evaluation may be appropriate.  
The methodological aim of the present dissertation concerns the application of 
economic evaluation only of quality improvements that are expected to eventually 
affect health, but for which evidence on the occurrence of patient-relevant outcomes 
may not be achievable. The expectation that they eventually influence health would 
justify the application of economic evaluation to establish their value for money. 
 
6.3. PROCURING	EVIDENCE	ON		
THE	IMPACT	OF	QUALITY	IMPROVEMENTS	
More approaches have been proposed for the evaluation of quality improvements, but 
the proper study design remains yet unresolved. Quality improvement is often 
obtained through multifaceted, complex interventions, in which more initiatives are 
launched concomitantly. This could include the introduction of new technology, 
education of healthcare personnel and patients, and organizational changes[26,139]. 
When more elements are put into practice simultaneously, it becomes increasingly 
difficult to command all mechanisms and identify those triggering the potential effect 
of the intervention[26]. Establishing the effect of the individual components of a 
complement intervention requires substantial knowledge of potential relationships 
between the different elements and a considerable amount of data to support analyses. 
Likewise, with greater ‘distance’ between the intervention and impact on patient-
relevant outcomes, it becomes more difficult to establish a clinically and statistically 
significant relationship between the intervention and final impact on health[23]. Due 
to the often-high complexity of interactions between the different elements of quality 
improvements and influencing factors, it has been argued that it is next to impossible 
to evaluate the impact of quality improvements satisfactorily through the use of the 
conventional methods of EBM[26,69,139]. It might furthermore be argued that 
evaluation of quality improvements by currently available methods may not 
sufficiently capture all impact of interventions on patient-relevant outcomes; 
especially if impact is achieved gradually over a long time frame or through 
continuous processes such as dissemination of knowledge or organizational 
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changes[69,139]. To overcome some of the difficulties in procuring evidence on the 
effectiveness of quality improvements, QIs may be employed as surrogate for patient-
relevant outcomes, as these may be more sensitive to changes caused by interventions. 
QIs may, however, not reflect impact on health, per se, as requested in economic 
evaluation.[23,27]  
Due to the challenges in applying conventional evaluation for quality improvements, 
the application of conventional EBM evaluation methods for establishing the 
correlation between interventions and outcomes is highly disputed. It has even been 
argued that it should be completely refrained from.[26,69,139] In counter-argument 
against this stance, it might be reasoned that not establishing evidence for the 
effectiveness and value for money of interventions entails the risk of shelving the great 
opportunities that quality improvement holds. This might occur in consequence of 
implementation of ineffective quality ‘improvements’ or rejection of quality 
improvements in favor of other interventions for which the value for money is known. 
Failing to provide some kind of evidence on the expected impact of quality 
improvements may thus potentially cause opportunity costs and be regarded equally 
ill-considered[18].  
The fundamental challenge of how to procure evidence on the impact of quality 
improvements was beyond the scope of the present dissertation. Instead, this 
dissertation revolves around the potentials of undertaking economic evaluation of 
quality improvements when evidence on the expected correlation between 
interventions and QIs (φ1) has been acquired[1]. The focus is on the requirements for 
QIs to be valuable in the context of economic evaluation and on how economic 
evaluation may be designed to incorporate QIs when these have been used for 
outcome measure in quality improvements. Prior knowledge on the requirements to a 
QI is valuable in the design phase for studies intended to establish the impact of 
quality improvements as it enables the incorporation of these contemplations when 
the correlation φ1 needs to be established.  
 
6.4. USING	QUALITY	INDICATORS	IN	ECONOMIC	EVALUATION	
In the present dissertation, it is proposed that when QI are used for effect measure for 
quality improvements, it might still be possible to generate estimates of expected NB 
of the interventions to inform decision-making. The presented framework and 
recommendations for estimation of NB of interventions based on QIs are reasonably 
consistent with the recommendations on use of clinical, intermediate endpoints to 
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estimate the NB of interventions[1,53] Modeling expected NB based on surrogate, 
physiological outcomes remains disputed, but is more or less accepted when 
appropriate caution is taken[13,53]. The experience with and recommendations on 
modeling based on clinical, intermediate endpoints may inform future work on the 
application of QIs to model expected NB of quality improvements. Over time the same 
acceptance might be achieved for modeling of NB-based QIs. 
In 1966 when quality evaluation and improvement was first couched as a scientific 
discipline, Donabedian queried “…but how precise do estimates of quality have to 
be?”[23]. This question poses the focal point of the present dissertation. The answer 
may not be straightforward and differs depending on what the intended use of the 
estimates is. If QIs are used to make inferences about the impact on health and 
consequently expected cost-effectiveness that interventions supply, a number of 
requirements may exist for them to be applicable. The correlation between QIs and 
final impact on health is in all likelihood affected by uncertainty, which may 
subsequently affect the decision uncertainty and increase the risk of making 
suboptimal decisions. Estimating NB based on QIs remains the inferior solution, due 
to the potential risk of misspecifications of the correlation φ2, the additional 
uncertainty of φ2, and consequent erroneous NB estimations. If it is possible, within 
reason, to acquire evidence on the correlation between interventions and the 
occurrence of patient-relevant outcomes this would be the recommended 
approach[1,53]. However, the lack of evidence on impact on patient-relevant 
outcomes remains a core issue in work with quality improvement. The issue will 
expectedly only persist, necessitating deliberations of the appropriate handling of it in 
a health economic context. Use of DAM and the handling of QIs as an extra 
intermediate link may be a way forward under the expectation that uncertainty and the 
potential cost of uncertainty are sufficiently highlighted. Analyses may yet be 
performed and may provide useful information, despite the uncertainty pertaining to 
the available evidence. The accuracy of economic evaluations is not as important as 
how the information they convey affects the decision, which it is intended to aid[13].  
Through the execution of the studies I-IV[1–4], four steps have been identified that 
may guide the execution of economic evaluation of quality improvements, when QIs 
have been used for outcome (Box 5). To enable later economic evaluation of quality 
improvements, for which QIs are applied for outcome, these steps should be 
considered even before initiating gathering of evidence.  
For quality improvements that are expected to ultimately affect health, only outcome-
validated QIs should be used to enable subsequent economic evaluation of the 
intervention[23,53,67]. Furthermore, it should be considered whether the applied QI 
embraces all relevant impact on health. Otherwise it might be necessary to employ 
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more, mutually exclusive QIs to reflect the entirety of the effect of interventions[1]. 
If non-validated QIs are employed, analyses potentially become uninformative or, 
worse, misleading. This may eventually result in benefits foregone if either cost-
ineffective interventions are used or cost-effective interventions are rejected.  
 
If the relationship between QI(s) and patient-relevant outcome(s) is generally 
accepted, but not yet quantified, this should be done to enable further use of the 
correlation in DAM. It is critical that the correlation φ2 is correctly specified to avoid 
erroneous NB estimations; especially to avoid overestimation of the benefits involved 
with the quality improvement as measured via the QI[53]. This may include both the 
application of an appropriate model for the correlation and appropriate adjustment for 
factors known to influence the occurrence of the patient-relevant outcomes. As 
illustrated in study IV[4], adjustment for all relevant factors may prove itself difficult, 
for instance due to missing information on parameters of interest. The risk and 
potential consequences of unobserved confounding and bias should be deliberated 
when the correlation is established as the impact of these would not be reflected in 
VOI analyses. The more information that is available, and on less aggregate level, the 
more informative analyses may become and the smaller the risk of establishing 
confounded correlations. Adjustment for the characteristics of the setting and patient 
population in which the QI is used may furthermore ensure a better reflection of the 
expected impact of quality improvement for that specific context and consequently 
the soundness of analyses[105].  
The correlation parameter φ2 would be valid for the patient group, for which it is 
estimated. Ideally, it should be estimated for a reasonable homogeneous patient group 
to diminish the level of uncertainty pertaining to the parameter. Correlations estimated 
for highly specific groups would likely entail less uncertainty, leading to less decision 
I. Use only outcome-validated quality indicator(s) for outcome measure. 
The applied quality indicator(s) should be strongly related to patient-
relevant outcome(s). 
II. Estimate the expected correlation, φ2, between the applied quality 
indicator(s) and patient-relevant outcome(s), if it is not already 
established.  
III. Estimate the expected net benefit of interventions based on the quality 
indicator(s) by use of decision-analytic modeling.  
IV. Estimate and evaluate the expected cost of uncertainty related to the 
results, particularly the use of the quality indicator(s); the uncertainty 
parameter, φ2. 
Box 5. Listing of four steps to enable and execute economic evaluation of quality
improvements when quality indicators are used for outcome measure. 
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uncertainty. They would, however, potentially lack the transferability to analyses 
performed for other, dissimilar groups. As a result, the ‘global’ use of it would be 
hampered. The balance between specificity and ‘globality’ of a QI might be struck 
pragmatically, based on the grouping level relevant for decision-making. That is, 
struck, based on whether interventions expectedly will be offered to the patient group 
under investigation or not. Information on subgroups within that group is of less 
interest, as the decision whether to offer the intervention to the entire group or not 
would not change. This could be die to a desire of equal access to care within the 
group. For instance, it appears unlikely that all male AF patients would be offered a 
certain intervention and female AF patients not, even if the intervention appeared cost-
ineffective in the latter group. Estimation of the correlation parameter φ2 for the entire 
AF patient population would thus be more relevant for further use.  
When the correlation between QI(s) and patient-relevant outcome(s) has been 
established, the expected NB of interventions may be estimated by use of 
DAM[1,13,53]. The decision uncertainty and cost of uncertainty pertaining to the 
results should be evaluated and it should be considered whether resolving the 
uncertainty would be relevant to diminish the risk of making the wrong decision, 
based on the current level of evidence[1,49,61]. Use of the framework presented in 
this dissertation might consequently ease estimation of the cost-effectiveness of 
quality improvements where non-health-related endpoints have otherwise been 
applied, even when incremental costs are positive.  
 
6.5. EVALUATING	THE	VALUE	FOR	MONEY	OF		
QUALITY	IMPROVEMENTS	–	FUTURE	OPPORTUNITIES	
In the present dissertation, it is argued that, if done sensibly and cautiously, using QIs 
in DAM may help inform policymakers on the potential value for money of quality 
improvements. This may result in more informed and consistent decision-making, as 
the impact of quality improvements may be evaluated on equal terms with other 
interventions in the healthcare system.  
The present framework may potentially be used for pilot economic evaluation of 
quality improvements, if evidence on impact on QIs of interventions is made available 
early during the execution of studies. This may be relevant even when patient-relevant 
outcomes are expected to eventually occur. Preliminary estimations of the potential 
health economic impact of interventions may provide early information on their 
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expected NB. This may enable early termination of studies and discarding of 
interventions that appear unlikely to provide a positive NB, although evidence on 
direct impact on health remains unexplored. This would be cost-saving compared to 
the completion of studies to establish evidence on the (lack of) impact of interventions 
on patient-relevant outcomes. Nonetheless, as emphasized, estimates of NB estimated 
through the use of the present framework would be subject to increased uncertainty 
due to the introduction of the correlation parameter φ2, which should be appraised 
critically when evaluating the validity of results.  
The use of the framework is in the present dissertation exemplified by the use of QIs 
in stroke prophylaxis in AF. The framework should however be transferable to other 
disease and treatment areas, by incorporation of other outcome-validated QIs relevant 
for the investigated decision problem. For instance, diabetes patients suffer an 
increased risk of various late complications, including foot ulcers that further increase 
the risk of leg amputations. These complications inevitably entail both a high personal 
as well as economic burden. Increased attention to early symptoms paid by patients 
and healthcare personnel alike may in part prevent these late complications of 
diabetes. Diabetes patients are consequently recommended regular foot care and 
examinations to diminish the risk of developing complication and for early detection 
of them in order to retain further worsening.[140,141] Accordingly, the proportion of 
diabetes patients receiving regular foot care is accepted as a process QI[20]. By 
different initiatives, it might be possible to increase the proportion of patients 
receiving regular foot care, which would then expectedly decrease the occurrence of 
diabetic foot ulcers and other complications. If the reduction in risk of late 
complications achieved by regular foot care were quantified, i.e. φ2 were established, 
it might be possible to estimate the NB of increasing the proportion of diabetes patient 
receiving regular foot care by use of the present framework. Other quality 
improvements may be evaluated in the same manner, as long as the necessary 
correlations can be established and the caveats presented in this dissertation are taken 
into account.  
As patient-centeredness is of increasing importance in healthcare delivery[22,63], the 
ability to valuate and incorporate e.g. patient preferences, satisfaction, and 
convenience of care, in evaluations is of increasing interest. The desire to incorporate 
more elements than cost-effectiveness in evaluation of interventions is not singular 
for quality improvements. In some therapy fields, the boundary for achievable 
efficacy and safety is almost reached. Consequently, further benefits of (new) 
therapies can only be achieved through improvements in other characteristics of 
therapy, e.g. in the convenience of care. For instance, it could be argued that the major 
benefit of NOACs compared to warfarin therapy is not an improved safety and 
effectiveness profile[30,31], but rather that the medication is more convenient for 
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patients and healthcare personnel alike[113]. To explicitly include patient-relevant 
elements of care, i.e. preferences towards interventions due to greater convenience 
etc., the CBA may be a useful approach to the economic evaluation of interventions. 
Using the CBA would enable the inclusion of more relevant aspects of care than 
HRQoL, as captured by the CUA, including elements of patient-centeredness and 
equity, insofar these are appropriately and reliably valuated. As explicated (cf. section 
3.3.1), there are however appreciable challenges to the application of CBA within 
healthcare. 
In addition, multi-criteria decision analysis might provide a potential decision support 
framework that enables the inclusion of more criteria in the decision-making process 
than is currently enabled in conventional economic evaluation. In multi-criteria 
decision analysis, the cost-effectiveness of intervention, as determined by 
conventional methods may constitute one out of more criteria deemed relevant for a 
specific decision problem. Hence, different aspects of quality in healthcare may be 
explicitly and systematically included in the decision analysis. The different criteria 
are subsequently weighted according to stakeholders’ preferences towards 
them.[142,143] Multi-criteria decision analysis thus enables explicit and transparent 
inclusion of other elements of importance for decision-making, which could include 
other attributes of quality in healthcare, such as equity concerns. 
The present dissertation has demonstrated some of the obstacles for application of 
health economic evaluation to the area of quality improvements. It also provides a 
contribution as to the opportunities for using QI as intermediate link in DAM to 
establish the value for money of quality improvements, when patient-relevant 
outcomes are not available. The application of economic evaluation to quality 
improvement requires great interdisciplinary cooperation with participation from 
diverse evaluation traditions and therefore also the acceptance and inclusion of 
different epistemologies. Compromises must be made and researchers in both quality 
improvement and economic evaluation must extend their hands to hopefully improve 
research. Researchers in the field of quality improvement should consider the purpose 
and use of QIs early in the design of studies if economic evaluation is under 
consideration. Researcher in economic evaluation should continue striving to develop 
the methods for economic evaluation for inclusion of evidence derived from other 
sources than EBM. The inclusion and merging of more scientific methodologies may 
improve our understanding of the mechanisms leading to quality improvement in 
healthcare, benefitting patients and the society as a whole.[26,69,139] 
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Appendix	A. Paper	I:	What	is	the	value	of	quality	indicators	for	informed	decision‐making	in	healthcare?	A	Bayesian	decision	theoretical	and	value	of	information	analysis	perspective	
TITLE:	WHAT	IS	THE	VALUE	OF	QUALITY	INDICATORS	FOR	INFORMED	
DECISION‐MAKING	IN	HEALTHCARE?	A	BAYESIAN	DECISION	
THEORETICAL	AND	VALUE	OF	INFORMATION	ANALYSIS	PERSPECTIVE		
	
Abstract: 
The existence of budgetary constraints within healthcare systems is increasingly 
recognized and prompts additional considerations of cost-effectiveness of 
interventions before their introduction. A challenge that has arisen within the last 
decade is the increasing use of quality indicators (QIs) as outcome for interventions 
that improve quality and safety in healthcare. QIs aim at quantifying the effect of 
quality improvements and are often not measures that allow for establishment of cost-
effectiveness, based on generally acknowledged threshold values, as they do not 
reflect health gains per se. Opportunities to identify cost-effective quality 
improvements may be missed if their value for money cannot be established by use of 
conventional health economic methods. The aim here was to apply Bayesian decision 
theory and value of information (VOI) analysis to 1) investigate the requirements for 
QIs to be applicable for economic evaluation and 2) investigate under which 
circumstances QIs may be used to aid decision-making. Thus, Bayesian decision 
theory and VOI analysis were used to establish a framework to identify requirements 
for acceptable QIs and for evaluation of uncertainty when applying QIs for estimation 
of cost-effectiveness of interventions. Use of QIs introduces an intermediate link in 
the relationship between interventions and expected net benefit, which increases the 
total uncertainty pertaining to results. This uncertainty carries a potential cost, 
interpreted as expected value of perfect parameter information, which should be 
compared to the expected cost and benefits of resolving that uncertainty. 
Requirements for an acceptable QI include a correlation between the intervention and 
the QI and an established correlation between the QI and patient-relevant outcomes. 
If these correlations are misspecified, the validity of cost-effectiveness results may be 
compromised. Bayesian decision theory and VOI analysis may comprise a viable 
framework for evaluation of the cost-effectiveness of quality improvement, allowing 
for more informed decision-making. 
AS Vestergaard, LH Ehlers 
Submitted[1] 

 
95 
Appendix	B. Paper	II:	Effect	of	Anticoagulation	on	Hospitalization	Costs	After	Intracranial	Hemorrhage	in	Atrial	Fibrillation	–	A	Registry	Study	
TITLE:	EFFECT	OF	ANTICOAGULATION	ON	HOSPITALIZATION	COSTS	
AFTER	INTRACRANIAL	HEMORRHAGE	IN	ATRIAL	FIBRILLATION	–	A	
REGISTRY	STUDY	
 
 
Abstract: 
Background and purpose Intracranial hemorrhage (ICH) is the most feared adverse 
event with oral anticoagulant therapy (OAC) in patients with atrial fibrillation (AF). 
The health economic aspects of resuming OAC following ICH are unknown. The aim 
was to estimate hospitalization costs of thromboembolism and hemorrhage 
subsequent to ICH in two patient groups with AF surviving the first 90 days post-ICH; 
1) patients resuming warfarin therapy within 90 days post-ICH and 2) patients 
discontinuing therapy. 
Methods Retrospective data from Danish national registries were linked to identify 
patients with AF who suffered ICH between 1 January 1997 and 1 April 2011. Study 
start was 90 days after incident ICH. Mortality was evaluated by use of the Kaplan-
Meier estimate. Occurrence of hospitalization-requiring thromboembolism and 
hemorrhage was used to estimate hospitalization costs by linkage of ICD-10 codes to 
Danish Diagnosis-Related Group tariffs. The impact of resuming warfarin therapy on 
average, 3-year hospitalization costs was estimated by use of regression analysis 
adjusted for between-group differences in baseline characteristics. 
Results In the inclusion period 2,162 patients suffered ICH; 1,098 survived the first 
90 days and were included for analysis and of these 267 resumed warfarin therapy. 
Therapy resumption reduced the mean 3-year hospitalization cost of hospitalized 
patients significantly by US$1,588[95%CI:-2,925;-251] and was significantly 
correlated with fewer hospitalization days per hospitalized patient(-4.6[95%CI:-7.6;-
1.6]). The marginal effect of therapy resumption on hospitalization costs per patient 
was US$-407[95%CI:-815;2].     
Conclusions Resuming warfarin therapy within 90 days after ICH in patients with AF 
is associated with a decrease in average hospitalization costs.
AS Vestergaard, F Skjøth, GYH Lip, TB Larsen 
Stroke (2016) 47(4):979-85[2]   
DOI: 10.1161/STROKEAHA.115.012338  
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Appendix	C. Paper	III:	A	Health	Economic	Evaluation	of	Stroke	Prevention	in	Atrial	Fibrillation:	Guideline	Adherence	Versus	the	Observed	Treatment	Strategy	Prior	to	2012	in	Denmark	
TITLE:	A	HEALTH	ECONOMIC	EVALUATION	OF	STROKE	PREVENTION	IN	
ATRIAL	FIBRILLATION:	GUIDELINE	ADHERENCE	VERSUS	THE	OBSERVED	
TREATMENT	STRATEGY	PRIOR	TO	2012	IN	DENMARK		
 
 
Abstract: 
Background In 2012 the European Society of Cardiology published new guidelines 
on pharmacological stroke prophylaxis in non-valvular atrial fibrillation. The health 
economics of adhering to these guidelines in clinical practice remain to be elucidated.  
Objectives This paper offers a health economic evaluation of two stroke-prophylactic 
treatment strategies: complete national adherence to the European Society of 
Cardiology guideline on stroke prophylaxis in atrial fibrillation versus stroke-
prophylactic treatment prior to 2012 in Denmark. 
Methods A cost-utility analysis was performed to compare two treatment strategies. 
The first strategy reflected national guideline adherence with use of non-vitamin K 
antagonist oral anticoagulants (i.e. dabigatran etexilate), warfarin, and no treatment. 
The second strategy reflected observed stroke prophylaxis prior to 2012 with 
utilization of warfarin, acetylsalicylic acid, and no treatment. A Danish health sector 
perspective was adopted. A Markov model was designed and populated with 
information on input parameters from the literature and local cost data. A modeled 
patient cohort was constructed with a risk profile intended to reflect that of the Danish 
patient population with atrial fibrillation. The applied outcome was quality-adjusted 
life-years (QALYs). 
Results The incremental cost-effectiveness ratio amounted to €3557 per QALY for 
the guideline-adherent treatment strategy compared with the pre-2012 treatment 
strategy. This ratio is below a threshold of €25,000 (£20,000) per QALY. Sensitivity 
analyses revealed that the result was largely robust. All analyses found the guideline-
adherent treatment strategy to be cost-effective.   
Conclusions Guideline adherence is a cost-effective treatment strategy compared with 
the strategy employed prior to 2012 for pharmacological stroke prophylaxis in atrial 
fibrillation.
AS Vestergaard, LH Ehlers  
PharmacoEconomics (2015) 33:967–79[3]  
DOI: 10.1007/s40273-015-0281-z 
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Appendix	D. Paper	IV:	The	importance	of	mean	time	in	therapeutic	range	for	complication	rates	in	warfarin	therapy	of	atrial	fibrillation:	a	meta‐regression	analysis	
TITLE:	THE	IMPORTANCE	OF	MEAN	TIME	IN	THERAPEUTIC	RANGE	FOR	
COMPLICATION	RATES	IN	WARFARIN	THERAPY	OF	ATRIAL	
FIBRILLATION:	A	META‐REGRESSION	ANALYSIS	
	
Abstract: 
Background: Anticoagulation with warfarin is used for stroke prophylaxis in atrial 
fibrillation (AF) and quality in warfarin therapy is often summarized by the time 
patients spend within the therapeutic range (percent time in therapeutic range, TTR). 
The correlation between TTR and occurrence of complications during therapy has 
been established, but the influence of patient characteristics in that respect remains 
undetermined.  
Objective: To examine the association between TTR and complications with 
adjustment for differences in relevant patient cohort characteristics. 
Methods: A literature search was conducted in MEDLINE and Embase (2005-2015) 
to identify studies reporting on use of warfarin therapy of patients with AF and the 
occurrence of hemorrhage and thromboembolism. The association between mean 
TTR and major bleeding (MB) and stroke/systemic embolism (SSE) was analyzed by 
random-effects meta-regression with and without adjustment for relevant clinical 
cohort characteristics. 
Results: Of 2169 papers, 35 papers met pre-specified inclusion criteria, holding 
relevant information on 31 patient cohorts. In univariable meta-regression, increasing 
mean TTR was significantly associated with a decreased rate of both MB and SSE.  
However, after adjustment mean TTR was no longer significantly associated with 
SSE. The proportion of residual variance composed by between-study heterogeneity 
was substantial for all analyses. 
Conclusions: Although higher mean TTR was associated with lower complication 
rates, the strength of the association was decreased when adjusting for differences in 
relevant clinical characteristics of the patient cohorts. This study suggests that mainly 
the safety of warfarin therapy increases with higher mean TTR, whereas effectiveness 
appears not to be substantially improved. 
AS Vestergaard, F Skjøth, TB Larsen, LH Ehlers 
Submitted[4] 
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